Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
J Viral Hepat
    September 2021
  1. CAVEN M, Baiano CX, Robinson EM, Stephens B, et al
    Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    J Viral Hepat. 2021 Sep 15. doi: 10.1111/jvh.13614.
    >> Share

  2. MARCELLIN F, Di Beo V, Esterle L, Abgrall S, et al
    Post-HCV cure self-reported changes in physical activity, eating behaviors, and fatigue in people living with HIV (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2021 Sep 2. doi: 10.1111/jvh.13605.
    >> Share

    August 2021
  3. PALMER AY, Chan K, Gold J, Layton C, et al
    A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
    J Viral Hepat. 2021 Aug 20. doi: 10.1111/jvh.13596.
    >> Share

  4. BALL LE, Agana B, Comte-Walters S, Rockey DC, et al
    Hepatitis C Virus Treatment with Direct Acting Antivirals Induces Rapid Changes in the Hepatic Proteome.
    J Viral Hepat. 2021 Aug 11. doi: 10.1111/jvh.13593.
    >> Share

  5. KNOP V, Hoppe D, Vermehren J, Troetschler S, et al
    Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 year follow-up of a prospective longitudinal study.
    J Viral Hepat. 2021 Aug 3. doi: 10.1111/jvh.13587.
    >> Share

  6. HUPPE D, Stoehr A, Buggisch P, Mauss S, et al
    The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real-world data from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 Aug 2. doi: 10.1111/jvh.13586.
    >> Share

    July 2021
  7. SANTOS-LIMA C, Souza-Marques B, Vieira F, Schinoni MI, et al
    Neuropsychological effects of direct-acting antiviral treatment for HCV subjects: a systematic review.
    J Viral Hepat. 2021 Jul 28. doi: 10.1111/jvh.13584.
    >> Share

  8. WANG Y, Zhao Z, Zhang H, Lin Q, et al
    Estimating the transmissibility of hepatitis C: a modelling study in Yichang City, China.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13582.
    >> Share

  9. DEL ROSARIO A, Eldredge JD, Doorley S, Mishra SI, et al
    Hepatitis C Virus Care Cascade in Persons Experiencing Homelessness in the United States in the Era of Direct-Acting Antiviral Agents: A Scoping Review.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13583.
    >> Share

  10. OHKI T, Satov K, Kondo M, Goto E, et al
    Effectiveness of direct acting antiviral agents for hepatitis C virus related recurrent hepatocellular carcinoma patients who had multiple courses of recurrence.
    J Viral Hepat. 2021 Jul 27. doi: 10.1111/jvh.13579.
    >> Share

  11. YOUSAFZAI MT, Bajis S, Alavi M, Grebely J, et al
    Treatment cascade of care for chronic hepatitis C virus infection globally: Systematic review and meta-analysis.
    J Viral Hepat. 2021 Jul 26. doi: 10.1111/jvh.13574.
    >> Share

  12. BISCHOFF J, Mauss S, Lutz T, Cordes C, et al
    Late presentation of chronic hepatitis C patients in the era of direct acting antivirals - Data from the German Hepatitis C-Registry.
    J Viral Hepat. 2021 Jul 21. doi: 10.1111/jvh.13576.
    >> Share

  13. BARDSLEY M, Heinsbroek E, Harris R, Croxford S, et al
    The Impact Of Direct-Acting Antivirals On Hepatitis C Viraemia Among People Who Inject Drugs In England; Real-World Data 2011-2018.
    J Viral Hepat. 2021 Jul 16. doi: 10.1111/jvh.13575.
    >> Share

  14. VARCHETTA S, Mele D, D'Ambrosio R, Perbellini R, et al
    A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C.
    J Viral Hepat. 2021 Jul 6. doi: 10.1111/jvh.13570.
    >> Share

  15. ERICE A, Varillas-Delgado D, Caballero C
    Prevalence and characteristics of hepatitis C virus infection detected by extended screening of working-age adults in Madrid (Spain).
    J Viral Hepat. 2021 Jul 5. doi: 10.1111/jvh.13564.
    >> Share

    June 2021
  16. KIM HP, Edwards A, Reeve BB, Golin CE, et al
    Symptoms and Functioning Improve after Chronic Hepatitis C Cure as Assessed by the Memorial Symptom Assessment Scale and PROMIS Measures.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13561.
    >> Share

  17. KUMADA T, Toyoda H, Yasuda S, Tada T, et al
    Long-term outcomes of viral eradication in patients with hepatitis C virus infection and mild hepatic fibrosis.
    J Viral Hepat. 2021 Jun 29. doi: 10.1111/jvh.13562.
    >> Share

  18. KANG Q, Xu J, Luo H, Tan N, et al
    Direct antiviral agent treatment leads to rapid and significant fibrosis regression after HCV eradication.
    J Viral Hepat. 2021 Jun 9. doi: 10.1111/jvh.13558.
    >> Share

    May 2021
  19. BROWN C, Siegele M, Wright M, Cook C, et al
    Injecting network structure determines the most efficient strategy to achieve Hepatitis C elimination in people who inject drugs.
    J Viral Hepat. 2021 May 28. doi: 10.1111/jvh.13554.
    >> Share

  20. SMITH DA, Bradshaw D, Mbisa J, Manso CF, et al
    Real World SOF/VEL/VOX Retreatment Outcomes and Viral Resistance Analysis for HCV Patients with Prior Failure to DAA Therapy.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13549.
    >> Share

  21. OHLENDORF V, Schafer A, Christensen S, Heyne R, et al
    Only partial improvement in health-related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real-world setting- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13546.
    >> Share

  22. LIU PC, Chan C, Huang YH, Chen YJ, et al
    Genetic Variants Associated With Serum Alanine Aminotransferase Levels Among Patients With Hepatitis C Virus Infection: A Genome-Wide Association Study.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13550.
    >> Share

  23. KIM S, Powell J, Naugle J, Ricco M, et al
    Patient-Reported Experiences with Direct Acting Antiviral Therapy in an Integrated Model of Hepatitis C Care in Homeless Shelters.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13544.
    >> Share

  24. MCDONALD SA, Barclay ST, Innes HA, Fraser A, et al
    Uptake of interferon-free DAA therapy among HCV-infected decompensated cirrhosis patients and evidence for decreased mortality.
    J Viral Hepat. 2021 May 18. doi: 10.1111/jvh.13543.
    >> Share

  25. COWAN E, Hardardt J, Brandspiegel S, Eiting E, et al
    Care cascade of patients with Hepatitis C and HIV identified by Emergency Department screening.
    J Viral Hepat. 2021 May 1. doi: 10.1111/jvh.13529.
    >> Share

    April 2021
  26. CALVARUSO V, Petta S, Cacciola I, Cabibbo G, et al
    Liver and Cardiovascular Mortality After Hepatitis C Virus Eradication by DAA: data from RESIST-HCV Cohort.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13523.
    >> Share

  27. FIMMEL CJ, Khan MQ, Belopolsky Y, Imas P, et al
    Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program.
    J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524.
    >> Share

  28. HERNANDEZ C, Trujillo D, Turner CM, Sicro S, et al
    Reaching trans-women in San Francisco for efforts to eliminate hepatitis C.
    J Viral Hepat. 2021 Apr 24. doi: 10.1111/jvh.13521.
    >> Share

  29. GOUTZAMANIS S, Spelman T, Harney B, Dietze P, et al
    Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    J Viral Hepat. 2021 Apr 20. doi: 10.1111/jvh.13516.
    >> Share

  30. LEE TH, Chan A, Bryan W, Park L, et al
    Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.
    J Viral Hepat. 2021;28:630-636.
    >> Share

    March 2021
  31. BUTT AA, Yan P
    Natural History of Hepatitis C Virus Infection in a Large National Seroconversion Cohort in the Direct Acting Antiviral Agent Era: Results from ERCHIVES.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13507.
    >> Share

  32. LIU CH, Sun HY, Hsieh SM, Liu WC, et al
    Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct acting antivirals and antiretroviral therapy.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13502.
    >> Share

  33. BAIANO CX, Caven M, Robinson EM, Dillon JF, et al
    Evaluating and communicating hepatitis C cascades of care data in Tayside, Scotland: A journey towards elimination.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13505.
    >> Share

  34. MACGREGOR L, Ward Z, Martin NK, Nicholls J, et al
    The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK.
    J Viral Hepat. 2021 Mar 24. doi: 10.1111/jvh.13503.
    >> Share

  35. MACIAS J, Tellez F, de Los Santos I, Morano LE, et al
    Impact of recent drug use on the efficacy of Elbasvir/Grazoprevir for HCV-infected people on opioid agonist therapy.
    J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13496.
    >> Share

  36. JIANG JJ, Shiels MS, O'Brien TR
    Death Certificates Compared to SEER-Medicare Data for Surveillance of Liver Cancer Mortality Due to Hepatitis B or Hepatitis C Infection.
    J Viral Hepat. 2021 Mar 15. doi: 10.1111/jvh.13498.
    >> Share

  37. PERICOT-VALVERDE I, Rennert L, Heo M, Akiyama MJ, et al
    Rates of perfect self-reported adherence to direct-acting antiviral therapy and its correlates among people who inject drugs on medications for opioid use disorder: The PREVAIL study.
    J Viral Hepat. 2021;28:548-557.
    >> Share

    February 2021
  38. BAR N, Levy S, Deutsch L, Leshno M, et al
    Hepatitis C related cognitive impairment: impact of viral and host factors and response to therapy.
    J Viral Hepat. 2021 Feb 23. doi: 10.1111/jvh.13492.
    >> Share

  39. BANDERA A, Lorenzini P, Taramasso L, Cozzi-Lepri A, et al
    The impact of DAA-mediated HCV eradication on CD4(+) and CD8(+) T lymphocyte trajectories in HIV/HCV coinfected patients: data from the ICONA Foundation Cohort.
    J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13488.
    >> Share

  40. VEGAS JJ, Flores-Herrera J, Latasa P, Garrido-Estepa M, et al
    Reduction in hepatitis C-related hospitalisations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences.
    J Viral Hepat. 2021 Feb 18. doi: 10.1111/jvh.13491.
    >> Share

  41. HARNEY BL, Brereton R, Whitton B, Pietrzak D, et al
    Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care.
    J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13487.
    >> Share

  42. TOKUCHI Y, Suda G, Kimura M, Maehara O, et al
    Changes in the estimated renal function after hepatitis C virus eradication with direct-acting antiviral agents: Impact of changes in skeletal muscle mass.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13484.
    >> Share

  43. FRAZZONI L, Sikandar U, Mazzella G, Fuccio L, et al
    A multimedia multilanguage web-based platform can assess and increase the awareness on HCV infection of Pakistani people living in Italy.
    J Viral Hepat. 2021 Feb 15. doi: 10.1111/jvh.13486.
    >> Share

  44. SAHAKYAN Y, Lee-Kim V, Bremner KE, Bielecki JM, et al
    Impact of direct acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis C: systematic review and meta-analysis.
    J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13482.
    >> Share

  45. VERGARA M, Miquel M, Vela E, Cleries M, et al
    Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents.
    J Viral Hepat. 2021 Feb 8. doi: 10.1111/jvh.13479.
    >> Share

  46. KREKULOVA L, Honzak R, Riley LW
    Viral hepatitis C pandemic: challenges and threats to its elimination.
    J Viral Hepat. 2021 Feb 6. doi: 10.1111/jvh.13480.
    >> Share

  47. WEI YJ, Hsu PY, Lee JJ, Niu SW, et al
    Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uremic patients receiving hemodialysis in Taiwan- the FORMOSA-LIKE group.
    J Viral Hepat. 2021 Feb 3. doi: 10.1111/jvh.13477.
    >> Share

  48. PRITCHARD H, Hwang JP, Angelidakis G, Yibirin M, et al
    Hepatitis B Virus Reactivation in Cancer Patients Receiving Direct-Acting Antivirals for Hepatitis C Virus Infection.
    J Viral Hepat. 2021 Feb 1. doi: 10.1111/jvh.13478.
    >> Share

    January 2021
  49. LOCKART I, Hajarizadeh B, Alavi M, Davison S, et al
    Title: Hepatitis C virus cure before hepatocellular carcinoma diagnosis is associated with improved survival.
    J Viral Hepat. 2021 Jan 22. doi: 10.1111/jvh.13475.
    >> Share

  50. WILDER JM, Evon DM, Jean Proeschold-Bell R, Yao J, et al
    Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives.
    J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474.
    >> Share

  51. SU X, Zhao X, Deng JL, Li SN, et al
    Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis.
    J Viral Hepat. 2021 Jan 16. doi: 10.1111/jvh.13469.
    >> Share

  52. CHEN B, Ma ZH, Xu B, Chang H, et al
    Evaluation of seven Rapid Diagnostic Tests for Detection of Hepatitis C Virus Antibodies in China.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13466.
    >> Share

  53. SHUMBUSHO F, Liu AF, Kateera F, Kabahizi J, et al
    Risk factors for difficult-to-treat Hepatitis C Virus genotype 4r in Rwanda and implications for elimination in sub-Saharan africa.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13467.
    >> Share

  54. FRANCESCA ROMANA P, Francesco S, Massimo S, Antonio Giulio B, et al
    Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care center: results of the Telepass project.
    J Viral Hepat. 2021 Jan 9. doi: 10.1111/jvh.13465.
    >> Share

    December 2020
  55. O'GORMAN P, Strahan O, Ferguson D, Monaghan A, et al
    Improvement in cognitive impairment following a 12-week aerobic exercise intervention in individuals with non-cirrhotic chronic hepatitis C.
    J Viral Hepat. 2020 Dec 28. doi: 10.1111/jvh.13460.
    >> Share

  56. FABBIANI M, Lombardi A, Colaneri M, Del Poggio P, et al
    High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
    J Viral Hepat. 2020 Dec 11. doi: 10.1111/jvh.13454.
    >> Share

  57. GORRIS M, van der Lecq BM, van Erpecum KJ, de Bruijne J, et al
    Treatment for Chronic Hepatitis E Virus Infection: A Systematic Review and Meta-analysis.
    J Viral Hepat. 2020 Dec 10. doi: 10.1111/jvh.13456.
    >> Share

  58. CHAN K, Elsum I, Gold J, Layton C, et al
    Increasing hepatitis C testing and linkage to care: Results of a testing campaign with incentives at primary care clinics in Melbourne, Australia.
    J Viral Hepat. 2020 Dec 1. doi: 10.1111/jvh.13447.
    >> Share

    November 2020
  59. TADA T, Toyoda H, Kumada T, Kurisu A, et al
    Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13444.
    >> Share

  60. WHITELEY D, Speakman E, Elliott L, Davidson K, et al
    Provider-related barriers and enablers to the provision of hepatitis C treatment by General Practitioners in Scotland: A behaviour change analysis.
    J Viral Hepat. 2020 Nov 20. doi: 10.1111/jvh.13443.
    >> Share

  61. RAZAVI H
    The cost effectiveness of hepatitis C virus elimination in low and middle-income countries.
    J Viral Hepat. 2020 Nov 17. doi: 10.1111/jvh.13442.
    >> Share

  62. WEINHEIMER-HAUS EM, Yu X, Singal AG, Naylor KB, et al
    Utilizing public health data to geotarget hepatitis C virus elimination approaches in urban and rural Michigan.
    J Viral Hepat. 2020 Nov 13. doi: 10.1111/jvh.13438.
    >> Share

  63. KIM D, Alshuwaykh OS, Cholankeril G, Wong RJ, et al
    Trends in Mortality in Hepatitis C Infection and Alcoholic Liver Disease based on Drug Overdose in the United States.
    J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13435.
    >> Share

  64. RIDRUEJO E, Pinero F, Mendizabal M, Silva M, et al
    Direct-Acting Antivirals Treatment Failure in Genotype 2 Hepatitis C chronic Infection.
    J Viral Hepat. 2020 Nov 4. doi: 10.1111/jvh.13433.
    >> Share

  65. KAPADIA SN, Katzman C, Fong C, Eckhardt BJ, et al
    Hepatitis C Testing and Treatment Uptake among Young People who Use Opioids in New York City: A Cross-Sectional Study.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13437.
    >> Share

  66. WU D, Hu S, Chen G, Jiao C, et al
    Association of Hepatitis C Infection and Risk of Kidney Cancer: A Systematic Review and Meta-analysis of Observational Studies.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13434.
    >> Share

  67. SHEU MJ, Liang FW, Lu TH
    Hepatitis C virus infection mortality trends according to three definitions with special concern for the baby boomer birth cohort.
    J Viral Hepat. 2020 Nov 3. doi: 10.1111/jvh.13436.
    >> Share

    October 2020
  68. GALLACHER J, McPherson S
    Progress towards micro-elimination of hepatitis C in the custodial setting.
    J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13428.
    >> Share

  69. FAHNOE U, Pedersen MS, Solund C, Ernst A, et al
    Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.
    J Viral Hepat. 2020 Oct 31. doi: 10.1111/jvh.13430.
    >> Share

  70. GOYAL A, Perelson AS, Kandathil AJ, Quinn J, et al
    HIV influences clustering and intracellular replication of hepatitis C virus.
    J Viral Hepat. 2020 Oct 30. doi: 10.1111/jvh.13429.
    >> Share

  71. IBRAHIM ES, Abdel-Samiee M, Youssef MI, El-Shazly H, et al
    Variceal Recurrence 4 Years post Endoscopic Band Ligation in Hepatitis C Patients who Achieved Sustained Virological Response with Oral Direct Acting Antiviral Therapy.
    J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13426.
    >> Share

  72. REYES-URUENA J, Celly A, Moreno S, Majo X, et al
    Hepatitis C virus: testing rate and attrition at linkage to specialized care, Catalonia, Spain 2011-2016.
    J Viral Hepat. 2020 Oct 23. doi: 10.1111/jvh.13427.
    >> Share

  73. CHAN J, Kim JJ, Barrett BK, Hamadeh A, et al
    Cost-Effectiveness Analysis of Sofosbuvir and Velpatasvir in Chronic Hepatitis C Patients with Decompensated Cirrhosis.
    J Viral Hepat. 2020 Oct 16. doi: 10.1111/jvh.13419.
    >> Share

  74. LAURSEN TL, Villesen IF, Leeming DJ, Karsdal MA, et al
    Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.
    J Viral Hepat. 2020 Oct 15. doi: 10.1111/jvh.13416.
    >> Share

  75. MAFIRAKUREVA N, Lim AG, Khalid GG, Aslam K, et al
    Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
    J Viral Hepat. 2020 Oct 14. doi: 10.1111/jvh.13422.
    >> Share

  76. RAFIQUE S, Zahid S, Ali A, Tariq M, et al
    Genome wide methylation profiling of HCV pathogenesis to develop diabetes and diabetic complications.
    J Viral Hepat. 2020 Oct 13. doi: 10.1111/jvh.13417.
    >> Share

  77. POOLA S, Sanaka S, Sewell K, Tillmann HL, et al
    Hepatitis B Surface Antibody Titers and Hepatitis B Reactivation with Direct-Acting Antiviral Therapy for Hepatitis C.
    J Viral Hepat. 2020 Oct 12. doi: 10.1111/jvh.13421.
    >> Share

    September 2020
  78. MARTINEZ SANZ J, Vivancos MJ, Sanchez-Conde M, Gomez-Ayerbe C, et al
    Hepatitis C and HIV combined screening in primary care: a cluster randomized trial.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13413.
    >> Share

  79. JOHNSON PJ, Berhane S, Walker AJ, Gordon FH, et al
    Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection.
    J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408.
    >> Share

  80. ZHANG Y, Jiang X, Zhao Y, Xu Y, et al
    Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A Meta-analysis.
    J Viral Hepat. 2020 Sep 22. doi: 10.1111/jvh.13409.
    >> Share

  81. THAUNG YM, Simion Chasela C C, Chew KW, Minior T, et al
    Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus co-infected patients in Myanmar.
    J Viral Hepat. 2020 Sep 16. doi: 10.1111/jvh.13405.
    >> Share

  82. CHEN JY, Cheng PN, Chiu YC, Chiu HC, et al
    Persistent Augmentation of Central Arterial Stiffness Following Viral Clearance by Direct Acting Antivirals in Chronic Hepatitis C.
    J Viral Hepat. 2020 Sep 14. doi: 10.1111/jvh.13406.
    >> Share

  83. LINDGREN P, Lofvendahl S, Bradvik G, Weiland O, et al
    Reduced work absenteeism in patients with hepatitis C treated with second-generation direct-acting antivirals.
    J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13398.
    >> Share

  84. VAN DIJK M, Drenth JPH
    Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.
    J Viral Hepat. 2020 Sep 8. doi: 10.1111/jvh.13399.
    >> Share

  85. MIZOKAMI M, Liu LJ, Fujiyama N, Littman M, et al
    Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.
    J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13395.
    >> Share

  86. PRINCE DS, Pipicella JL, Fraser M, Alvaro F, et al
    Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or "re-diagnose" infections is effective in Australia.
    J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393.
    >> Share

    August 2020
  87. WADE AJ, Doyle JS, Draper B, Howell J, et al
    In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
    J Viral Hepat. 2020 Aug 29. doi: 10.1111/jvh.13391.
    >> Share

  88. VAN NUIL JI, Umutesi G, Shumbusho F, Kateera F, et al
    Improved quality of life following direct-acting antiviral treatment for chronic hepatitis C infection in Rwanda: Results from a clinical trial in sub-Saharan Africa (the SHARED study).
    J Viral Hepat. 2020 Aug 28. doi: 10.1111/jvh.13386.
    >> Share

  89. SYED TA, Cherian R, Lewis S, Sterling RK, et al
    Telemedicine HCV Treatment in Department of Corrections Results in High SVR In Era of Direct-Acting Antivirals.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13392.
    >> Share

  90. PFLUGER LS, Schulze Zur Wiesch J, Polywka S, Lutgehetmann M, et al
    Hepatitis delta virus propagation enabled by hepatitis C virus - scientifically intriguing; but is it relevant to clinical practice?
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13385.
    >> Share

  91. PHILLIPS C, O'Sullivan, Schulkind J, Jones CJ, et al
    Authors' reply to letter: In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care'.
    J Viral Hepat. 2020 Aug 27. doi: 10.1111/jvh.13389.
    >> Share

  92. SUNG JC, Wyatt B, Perumalswami PV, Branch A, et al
    Response to "Hepatitis C Cure Improved Patient-reported Outcomes in Patients with and without Liver Fibrosis in a Prospective Study at a Large Urban Medical Center".
    J Viral Hepat. 2020 Aug 25. doi: 10.1111/jvh.13381.
    >> Share

  93. GIULIANI R, Casigliani V, Fornili M, Sebastiani T, et al
    HCV micro-elimination in two prisons in Milan, Italy: a model of care.
    J Viral Hepat. 2020 Aug 20. doi: 10.1111/jvh.13376.
    >> Share

  94. MENDIZABAL M, Testa P, Rojas M, Colaci CS, et al
    Pilot study using the ECHO model to enhance linkage to care for patients with hepatitis C in the custodial setting.
    J Viral Hepat. 2020 Aug 19. doi: 10.1111/jvh.13374.
    >> Share

  95. MORA M, Goodyear T, Marcellin F, Shoveller J, et al
    Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH).
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13378.
    >> Share

  96. HAMADEH A, Haines A, Feng Z, Thein HH, et al
    Estimating chronic hepatitis C prevalence in British Columbia and Ontario, Canada using population-based cohort studies.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13373.
    >> Share

  97. RAHAL H, Boutros S, Farhat M, Kullar R, et al
    Estimating Pediatric Hepatitis C Prevalence in the United States.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13377.
    >> Share

  98. BARRE T, Nishimwe ML, Protopopescu C, Marcellin F, et al
    Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort).
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13380.
    >> Share

  99. MESSINA V, Russo A, Parente E, Russo G, et al
    Innovative procedures for micro-elimination of hcv infection in persons who use drugs.
    J Viral Hepat. 2020 Aug 18. doi: 10.1111/jvh.13375.
    >> Share

  100. PERPINAN E, Perez-Del-Pulgar S, Londono MC, Marino Z, et al
    Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8(+) T cells after direct-acting antiviral therapies.
    J Viral Hepat. 2020 Aug 2. doi: 10.1111/jvh.13370.
    >> Share

    July 2020
  101. CASTRO FILHO E, Piedade J, Castro R, Luz PM, et al
    Effectiveness of direct-acting agents for chronic hepatitis C treatment in South America: a systematic review and meta-analysis.
    J Viral Hepat. 2020 Jul 24. doi: 10.1111/jvh.13364.
    >> Share

  102. IRVIN R, Ntiri-Reid B, Kleinman M, Agee T, et al
    Sharing the Cure: Building Primary Care and Public Health Infrastructure to Improve the Hepatitis C Care Continuum in Maryland.
    J Viral Hepat. 2020 Jul 15. doi: 10.1111/jvh.13360.
    >> Share

  103. DAI CY, Huang JF, Chuang WL, Yu ML, et al
    Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy: some issues.
    J Viral Hepat. 2020 Jul 5. doi: 10.1111/jvh.13358.
    >> Share

  104. DIMOVA RB, Rude E, Talal AH
    Age and Risk-Factor Based Serologic Screening for Hepatitis C Virus among an Urban, High-Risk Population.
    J Viral Hepat. 2020 Jul 2. doi: 10.1111/jvh.13359.
    >> Share

    June 2020
  105. NANGIA G, Vierling JM, Kwo P, Brown DD, et al
    Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: integrated analysis from clinical trials.
    J Viral Hepat. 2020 Jun 28. doi: 10.1111/jvh.13357.
    >> Share

  106. DALBENI A, Romano S, Bevilacqua M, Piccoli A, et al
    Beneficial effects of DAAs on cardiac function and structure in hepatitis C patients with low-moderate liver fibrosis.
    J Viral Hepat. 2020 Jun 27. doi: 10.1111/jvh.13355.
    >> Share

  107. CHEN YC, Thio CL, Kamangar F, Cox AL, et al
    Evolving trends in the prevalence of hepatitis C virus antibody positivity among HIV-infected men in a community-based primary care setting.
    J Viral Hepat. 2020 Jun 24. doi: 10.1111/jvh.13354.
    >> Share

  108. YOUSIF MM, Ahmed H, Elsadek HM, Shendi AM, et al
    Real-World Safety and Effectiveness Of Retreatment Of Egyptian Chronic Hepatitis C Patients Not Responding to NS5A Inhibitor-Based Therapies.
    J Viral Hepat. 2020 Jun 21. doi: 10.1111/jvh.13349.
    >> Share

  109. HWA YOUNG C, Mai Thi H, Kim KA, Cho H, et al
    Association between viral hepatitis infection and Parkinson's disease: A population-based prospective study.
    J Viral Hepat. 2020 Jun 17. doi: 10.1111/jvh.13346.
    >> Share

  110. SAINE ME, Szymczak JE, Moore TM, Bamford LP, et al
    Determinants of Stigma among Patients with Hepatitis C Virus (HCV) Infection.
    J Viral Hepat. 2020 Jun 5. doi: 10.1111/jvh.13343.
    >> Share

  111. MINA M, Underwood A, Eltahla A, Wu BR, et al
    Anti-Envelope antibody responses in highly-exposed seronegative individuals may be associated with protection from HCV infection.
    J Viral Hepat. 2020 Jun 4. doi: 10.1111/jvh.13339.
    >> Share

  112. JACK K, Linsley P, JamesThomson B, Irving WL, et al
    How do people in prison feel about opt-out hepatitis C virus testing?
    J Viral Hepat. 2020 Jun 2. doi: 10.1111/jvh.13338.
    >> Share

  113. KAPLAN DE, Medvedeva E, Serper M
    Care Quality and Outcomes among U.S. Veterans with Chronic Hepatitis B in the Hepatitis C Direct Acting Antiviral Era.
    J Viral Hepat. 2020 Jun 2. doi: 10.1111/jvh.13340.
    >> Share

  114. POLLOCK KG, McDonald SA, Gunson R, McLeod A, et al
    Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype.
    J Viral Hepat. 2020 Jun 1. doi: 10.1111/jvh.13337.
    >> Share

    May 2020
  115. CONNOLEY D, Francis-Graham S, Storer M, Ekeke N, et al
    Detection, stratification, and treatment of hepatitis C positive prisoners in the United Kingdom prison estate: Development of a pathway of care to facilitate the elimination of hepatitis C in a London prison.
    J Viral Hepat. 2020 May 25. doi: 10.1111/jvh.13336.
    >> Share

  116. DE LEDINGHEN V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, et al
    Sofosbuvir-based regimens are suboptimal in patients with genotype 2 chronic hepatitis C infection: Real-life experience from the HEPATHER ANRS CO22 cohort.
    J Viral Hepat. 2020 May 21. doi: 10.1111/jvh.13321.
    >> Share

  117. DIETZ J, Kalinina OV, Vermehren J, Peiffer KH, et al
    Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.
    J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322.
    >> Share

  118. YE W, Li X
    Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis.
    J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13323.
    >> Share

  119. KIM NG, Kullar R, Khalil H, Saab S, et al
    Meeting the WHO Hepatitis C Virus Elimination Goal: Review of Treatment in Pediatrics.
    J Viral Hepat. 2020 May 9. doi: 10.1111/jvh.13317.
    >> Share

  120. ZHANG M, O'Keefe D, Iwamoto M, Sann K, et al
    High sustained viral response rate in patients with hepatitis C using generic sofosbuvir and daclatasvir in Phnom Penh, Cambodia.
    J Viral Hepat. 2020 May 2. doi: 10.1111/jvh.13311.
    >> Share

    April 2020
  121. CARRASCO I, Sainz T, Antoinette Frick M, de Ory SJ, et al
    Response to Direct Acting Antivirals for hepatitis C treatment in vertically HIV/HCV co-infected patients.
    J Viral Hepat. 2020 Apr 29. doi: 10.1111/jvh.13308.
    >> Share

  122. CHIU WN, Hung CH, Lu SN, Chen MY, et al
    Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection:a multicenter pooled analysis in Taiwan.
    J Viral Hepat. 2020 Apr 28. doi: 10.1111/jvh.13305.
    >> Share

  123. HONG CY, Sinn DH, Kang D, Paik SW, et al
    Incidence of extrahepatic cancers among individuals with chronic hepatitis B or C virus infection: Anationwide cohort study.
    J Viral Hepat. 2020 Apr 27. doi: 10.1111/jvh.13304.
    >> Share

  124. LI YR, Chen WC, Tsai WL, Cheng JS, et al
    Severe acute exacerbation of HCV infection in cancer patients who undergo chemotherapy without anti-viral prophylaxis.
    J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13302.
    >> Share

  125. AMOUGOU-ATSAMA M, Atangana PJA, Noah Noah D, Fewou Moundipa P, et al
    The role of hepatitis C virus genotypes and core mutations inhepatocellular carcinomain Cameroon.
    J Viral Hepat. 2020 Apr 16. doi: 10.1111/jvh.13303.
    >> Share

  126. ABU FREHA N, Wainstock T, Poupko L, Shemer Avni Y, et al
    Maternal hepatitis B or hepatitis C virus carrier s tatus and long-term infectious morbidity of the offspring: A population-based cohort study.
    J Viral Hepat. 2020 Apr 9. doi: 10.1111/jvh.13300.
    >> Share

  127. DESAI M, White E, Vora N, Gilson R, et al
    High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre-exposure prophylaxis.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13297.
    >> Share

  128. TSENG CW, Wu SF, Chen CY, Ho YC, et al
    Characteristics of Regulatory T Cell Function in Patients with Chronic Hepatitis B and C Coinfection.
    J Viral Hepat. 2020 Apr 3. doi: 10.1111/jvh.13298.
    >> Share

    March 2020
  129. VAN SANTEN DK, Sacks-Davis R, Doyle JS, Scott N, et al
    Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13294.
    >> Share

  130. JANJUA NZ, Wong S, Darvishian M, Butt ZA, et al
    The impact of SVR from direct acting antiviral and interferon- based treatments for HCV on hepatocellular carcinoma risk.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295.
    >> Share

  131. MEYER M, Bondy L, Koivu S, Koval J, et al
    New Hepatitis C Diagnoses in Ontario, Canada are associated with the Local Prescription Patterns of a Controlled Release Opioid.
    J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13292.
    >> Share

  132. BRADSHAW D, Vasylyeva TI, Davis C, Pybus OG, et al
    Transmission of hepatitis C virus in HIV-positive and PrEP-using MSM in England.
    J Viral Hepat. 2020 Mar 1. doi: 10.1111/jvh.13286.
    >> Share

  133. DARVISHIAN M, Wong S, Binka M, Yu A, et al
    Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies.
    J Viral Hepat. 2020;27:243-260.
    >> Share

    February 2020
  134. BIELEN R, Koc OM, Busschots D, Verrando R, et al
    Validation of hepatitis C virus RNA detection using capillary blood by fingerprick (GenXpert system)- Hepatitis C fingerprick study.
    J Viral Hepat. 2020 Feb 27. doi: 10.1111/jvh.13284.
    >> Share

  135. DENG Y, Campbell F, Han K, Theodore D, et al
    Randomized Clinical Trials Towards a Single-Visit Cure for Chronic Hepatitis C: Oral GSK2878175 and Injectable RG-101 in Chronic Hepatitis C Patients and Long-Acting Injectable GSK2878175 in Healthy Participants.
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13282.
    >> Share

  136. KNOP V, Mauss S, Goeser T, Geier A, et al
    Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C (HCV) infection receiving direct acting antiviral therapy- results from the German Hepatitis C-Registry (DHC-R).
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13280.
    >> Share

  137. MIRANDA AC, Mendez J, Serrao R, Vale F, et al
    Chronic hepatitis C treatment in HIV Co-infection in Portugal: Results from a cohort of 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
    J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13281.
    >> Share

  138. SHIHA G, Mousa N, Soliman R, Mikhail NN, et al
    Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13276.
    >> Share

  139. LIU Z, Mao X, Yu K, Suo C, et al
    Prevalence of HCV Resistance-Associated Substitutions amongTreatment FailurePatients receiving Direct-Acting Antiviral Agents.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13270.
    >> Share

  140. CIMINI E, Sacchi A, Grassi G, Casetti R, et al
    Persistent gamma delta T-cell dysfunction in HCV/HIV co-infection despite direct-acting antiviral therapy induced cure.
    J Viral Hepat. 2020 Feb 12. doi: 10.1111/jvh.13277.
    >> Share

  141. HIGASHI RT, Jain MK, Quirk L, Rich NE, et al
    Patient and Provider-Level Barriers to Hepatitis C Screening and Linkage to Care: A Mixed-Methods Evaluation.
    J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13278.
    >> Share

  142. FALADE-NWULIA O, Ward KM, McCormick S, Mehta SH, et al
    Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care.
    J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13274.
    >> Share

    January 2020
  143. SHIHA G, Soliman R, Serwah A, Mikhail NN, et al
    A same day "test and treat" model for chronic HCV and HBV infection: Results from two community-based pilot studies in Egypt.
    J Viral Hepat. 2020 Jan 30. doi: 10.1111/jvh.13268.
    >> Share

  144. MD SAID R, Mohd Zain R, Chan HK, Soelar SA, et al
    Find the Missing Millions: Malaysia's Experience with Nationwide Hepatitis C Screening Campaign in the General Population.
    J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13267.
    >> Share

  145. CAVEN M, Robinson EM, Eriksen AJ, Fletcher EH, et al
    Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project.
    J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269.
    >> Share

  146. LIU CH, Yang SS, Peng CY, Lin WT, et al
    Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    J Viral Hepat. 2020 Jan 25. doi: 10.1111/jvh.13265.
    >> Share

  147. TRAN TH, Nguyen BT, Nguyen TA, Pham TTP, et al
    Dried blood spots perform well to identify patients with active HCV infection in Vietnam.
    J Viral Hepat. 2020 Jan 24. doi: 10.1111/jvh.13263.
    >> Share

  148. POURMARZI D, Smirnov A, Hall L, Thompson H, et al
    Enablers and barriers for the provision of community-based HCV treatment: a case study of a real-world practice.
    J Viral Hepat. 2020 Jan 20. doi: 10.1111/jvh.13259.
    >> Share

  149. POORDAD F, Castro RE, Asatryan A, Aguilar H, et al
    Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir +/- Ribavirin in the TOPAZ-I and TOPAZ-II Trials.
    J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261.
    >> Share

  150. YAMAMICHI S, Miuma S, Wada T, Masumoto H, et al
    Deep sequence analysis of NS5A resistance-associated substitution changes in patients reinfected with the hepatitis C virus after liver transplantation.
    J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13256.
    >> Share

  151. FEDORCHENKO SV, Martynovych T, Klimenko Z, Yanchenko V, et al
    Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/ paritaprevir/ ritonavir, dasabuvir + sofosbuvir + r
    J Viral Hepat. 2020 Jan 2. doi: 10.1111/jvh.13254.
    >> Share

    December 2019
  152. IRVIN R, Chander G, Ward KM, Manogue S, et al
    Unreported Alcohol Use Was Common But Did Not Impact Hepatitis C Cure in HIV-Infected Persons Who Use Drugs.
    J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251.
    >> Share

    November 2019
  153. BOYLE A, Marra F, Peters E, Datta S, et al
    Eight weeks of Sofosbuvir/Velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis.
    J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239.
    >> Share

  154. CRESPO J, Cuadrado A, Perello C, Cabezas J, et al
    Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: data for designing a cost-effective elimination policy in Spain.
    J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13238.
    >> Share

  155. STARBIRD LE, Budhathoki C, Han HR, Sulkowski MS, et al
    Nurse case management to improve the hepatitis C care continuum in HIV co-infection: Results of a randomized controlled trial.
    J Viral Hepat. 2019 Nov 21. doi: 10.1111/jvh.13241.
    >> Share

  156. BHANDARI R, Morey S, Hamoodi A, Thompson C, et al
    High rate of hepatitis C re-infection following antiviral treatment in the North East England Prisons.
    J Viral Hepat. 2019 Nov 21. doi: 10.1111/jvh.13240.
    >> Share

  157. SUNG JC, Bosh C, Wyatt B, Miller M, et al
    Hepatitis C Cure Improved Patient-reported Outcomes in Patients with and without Liver Fibrosis in a Prospective Study at a Large Urban Medical Center.
    J Viral Hepat. 2019 Nov 19. doi: 10.1111/jvh.13234.
    >> Share

  158. BAJIS S, Grebely J, Hajarizadeh B, Applegate T, et al
    Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233.
    >> Share

  159. CACCIOLA I, Borgia F, Filomia R, Pitrone C, et al
    Outcome of cutaneous psoriasis in hepatitis C virus infected patients treated with Direct Acting Antiviral therapy.
    J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13230.
    >> Share

  160. MCDONALD SA, Pollock KG, Barclay ST, Goldberg DJ, et al
    Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
    J Viral Hepat. 2019 Nov 6. doi: 10.1111/jvh.13232.
    >> Share

    October 2019
  161. CARDOZO EF, Ji D, Lau G, Schinazi RF, et al
    Disentangling the life-spans of hepatitis C virus infected cells and intracellular vRNA replication-complexes during direct acting antiviral therapy.
    J Viral Hepat. 2019 Oct 31. doi: 10.1111/jvh.13229.
    >> Share

  162. SAHAKYAN Y, Wong W, Yi Q, Thein HH, et al
    Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: over 15 years of follow-up.
    J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13226.
    >> Share

  163. CARRAT F, Nahon P, Fontaine H, Pol S, et al
    Comparing Interferon-free with Interferon-based regimens in HCV patients: Rogers phenomenon and Simpson's paradox.
    J Viral Hepat. 2019 Oct 26. doi: 10.1111/jvh.13225.
    >> Share

  164. MARTIN P, Jadoul M, Pol S
    HCV in the Hemodialysis Population: treat now or later?
    J Viral Hepat. 2019 Oct 24. doi: 10.1111/jvh.13224.
    >> Share

  165. YANES-LANE M, Dussault C, Linthwaite B, Cox J, et al
    Using the barriers and facilitators to linkage to HIV care to inform hepatitis C virus (HCV) linkage to care strategies for people released from prison: Findings from a systematic review.
    J Viral Hepat. 2019 Oct 22. doi: 10.1111/jvh.13220.
    >> Share

  166. DANIEL KE, Saeian K, Rizvi S
    Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment.
    J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13218.
    >> Share

  167. RUSSO FP, Zanetto A, Gambato M, Bortoluzzi I, et al
    Hepatitis C virus eradication with direct acting antiviral improves insulin resistance.
    J Viral Hepat. 2019 Oct 9. doi: 10.1111/jvh.13215.
    >> Share

    September 2019
  168. PHILLIPS C, Schulkind J, O'Sullivan M, Edelman N, et al
    Improving access to care for People Who Inject Drugs: Qualitative evaluation of Project ITTREAT, an integrated community hepatitis C service.
    J Viral Hepat. 2019 Sep 30. doi: 10.1111/jvh.13214.
    >> Share

  169. RAO H, Song G, Li G, Yang Y, et al
    Safety and efficacy of coblopasvir and sofosbuvir in patients with genotype 1, 2, 3, and 6 HCV infections without or with compensated cirrhosis.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13208.
    >> Share

  170. BUCHANAN R, Cooper K, Grellier L, Khakoo SI, et al
    The testing of people with any risk factor for Hepatitis C in community pharmacies is cost effective.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13207.
    >> Share

  171. SAINZ T, Fernandez McPhee C, Dominguez-Rodriguez S, Hierro L, et al
    Longitudinal Evolution Of Vertically HIV/HCV Coinfected Vs HCV Monoinfected Children.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13206.
    >> Share

  172. VAN SANTEN DK, Boyd A, Bruisten S, Sonder GJ, et al
    Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups.
    J Viral Hepat. 2019 Sep 13. doi: 10.1111/jvh.13205.
    >> Share

  173. MILLER LS, Millman AJ, Lom J, Osinubi A, et al
    Defining the Hepatitis C Cure Cascade in an Urban Health System Using the Electronic Health Record.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199.
    >> Share

  174. IRELAND G, Simmons R, Hickman M, Harris R, et al
    Data linkage to monitor hepatitis C-associated end-stage liver disease and hepatocellular carcinoma inpatient stays in England.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13203.
    >> Share

  175. LAURSEN TL, Siggaard CB, Kazankov K, Sandahl TD, et al
    Time-dependent improvement of liver inflammation, fibrosis, and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C.
    J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13204.
    >> Share

    August 2019
  176. CATLETT B, Lamoury FMJ, Bajis S, Hajarizadeh B, et al
    Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.
    J Viral Hepat. 2019 Aug 26. doi: 10.1111/jvh.13196.
    >> Share

  177. JACKA B, Roy E, Hoj S, Minoyan N, et al
    Sexual behaviour as a risk factor for hepatitis C virus infection among people who inject drugs in Montreal, Canada.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13194.
    >> Share

  178. ROSA-HEZODE I, Chousterman M, Costes L, Labourdette C, et al
    Cascade of care for migrants tested Hepatitis C antibodies positive in France through a systematic screening program: the PRECAVIR study.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13192.
    >> Share

  179. TSAI MC, Lin CY, Hung CH, Lu SN, et al
    Evolution of Renal function under directly acting antivirals treatment for chronic hepatitis C: A real world experience.
    J Viral Hepat. 2019 Aug 21. doi: 10.1111/jvh.13193.
    >> Share

  180. FUJII H, Enomoto M, Murakami Y, Hagihara A, et al
    Last crusade against HCV: Direct-acting antiviral treatment for marginalized populations.
    J Viral Hepat. 2019 Aug 14. doi: 10.1111/jvh.13190.
    >> Share

  181. TRICKEY A, Fraser H, Lim AG, Walker JG, et al
    Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional, and country levels: a modelling study.
    J Viral Hepat. 2019 Aug 7. doi: 10.1111/jvh.13187.
    >> Share

  182. KRAMER J, Wolffram I, Fruh U, Batz O, et al
    Laboratory reform counteracts the WHO hepatitis C elimination strategy in Germany.
    J Viral Hepat. 2019 Aug 6. doi: 10.1111/jvh.13188.
    >> Share

  183. LUSIVIKA-NZINGA C, Fontaine H, Dorival C, Simony M, et al
    The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    J Viral Hepat. 2019 Aug 6. doi: 10.1111/jvh.13186.
    >> Share

    July 2019
  184. MAISA A, Semple S, Griffiths A, Ngui SL, et al
    Risk behaviours of homeless people who inject drugs during an outbreak of hepatitis C, Northern Ireland, 2016-2017.
    J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13184.
    >> Share

  185. MASON LMK, Veldhuijzen IK, Duffell E, van Ahee A, et al
    Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA: a systematic review.
    J Viral Hepat. 2019 Jul 22. doi: 10.1111/jvh.13182.
    >> Share

  186. WINETSKY D, Zucker J, Carnevale C, Theodore D, et al
    Attitudes, practices and perceived barriers to hepatitis C screening among medical residents at a large urban academic medical center.
    J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13181.
    >> Share

  187. MARRONE A, Ciotti M, Rinaldi L, Adinolfi LE, et al
    Hepatitis B and C virus infection and risk of hematological malignancies.
    J Viral Hepat. 2019 Jul 20. doi: 10.1111/jvh.13183.
    >> Share

  188. SCHAUER C, van Rijnsoever M, Gane E
    Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand.
    J Viral Hepat. 2019 Jul 19. doi: 10.1111/jvh.13179.
    >> Share

  189. GOUNTAS I, Sypsa V, Papatheodoridis G, Paraskevis D, et al
    A Hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece. Insights from a mathematical modeling study.
    J Viral Hepat. 2019 Jul 19. doi: 10.1111/jvh.13178.
    >> Share

  190. READ P, Gilliver R, Kearley J, Lothian R, et al
    Treatment Adherence and Support for People who Inject Drugs Taking Direct Acting Antiviral Therapy for Hepatitis C Infection.
    J Viral Hepat. 2019 Jul 12. doi: 10.1111/jvh.13175.
    >> Share

  191. DESHPANDE R, Stepanova M, Golabi P, Brown K, et al
    Prevalence, mortality and healthcare utilization among Medicare beneficiaries with Hepatitis C in Hemodialysis units.
    J Viral Hepat. 2019 Jul 11. doi: 10.1111/jvh.13173.
    >> Share

  192. IKEDA H, Watanabe T, Atsukawa M, Toyoda H, et al
    Evaluation of 8-Week Glecaprevir/Pibrentasvir Treatment in Direct-acting Antiviral -naive Non-cirrhotic Genotype 1 and 2 HCV Patients in a Real-world Setting in Japan.
    J Viral Hepat. 2019 Jul 6. doi: 10.1111/jvh.13170.
    >> Share

  193. PRONIER C, Fontaine H, Dorival C, Carrat F, et al
    Genetic diversity of genotype 6 HCV infections in France: epidemiology and consequences for treatment strategy.
    J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13171.
    >> Share

  194. MENDIZABAL M, Ridruejo E, Ceballos S, Sixto M, et al
    The ECHO model proved to be a useful tool to increase clinicians' self-effectiveness for care of patients with Hepatitis C in Argentina.
    J Viral Hepat. 2019 Jul 5. doi: 10.1111/jvh.13172.
    >> Share

    June 2019
  195. PELEG N, Issachar A, Sneh-Arbib O, Cohen-Naftaly M, et al
    Liver steatosis is a major predictor of poor outcomes in chronic hepatitis C patients with sustained virologic response.
    J Viral Hepat. 2019 Jun 27. doi: 10.1111/jvh.13167.
    >> Share

  196. VILLANI R, Monami M, Di Cosimo F, Fioravanti G, et al
    Direct-Acting antivirals for HCV treatment in older patients: a systematic review and meta-analysis.
    J Viral Hepat. 2019 Jun 27. doi: 10.1111/jvh.13169.
    >> Share

  197. ASSELAH T, Shafran SD, Bourgeois S, Lai CL, et al
    Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4, and 6 infection.
    J Viral Hepat. 2019 Jun 19. doi: 10.1111/jvh.13159.
    >> Share

  198. LU M, Wu KH, Li J, Moorman AC, et al
    Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure.
    J Viral Hepat. 2019 Jun 13. doi: 10.1111/jvh.13162.
    >> Share

  199. RAGONNET-CRONIN M, Hostager R, Hedskog C, Osinusi A, et al
    HIV co-infection is associated with increased transmission risk in patients with chronic hepatitis C virus.
    J Viral Hepat. 2019 Jun 13. doi: 10.1111/jvh.13160.
    >> Share

  200. DEGASPERI E, Galmozzi E, Facchetti F, Farina E, et al
    TLL1 Variants do not predict hepatocellular carcinoma development in hcv cirrhotic patients treated with direct-acting antivirals.
    J Viral Hepat. 2019 Jun 8. doi: 10.1111/jvh.13155.
    >> Share

    May 2019
  201. RIDRUEJO E, Cheinquer H, Marciano S, Mendizabal M, et al
    B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
    J Viral Hepat. 2019 May 29. doi: 10.1111/jvh.13148.
    >> Share

  202. WILLEMSE S, Smit C, Sogni P, Sarcletti M, et al
    Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV-patients with cirrhosis.
    J Viral Hepat. 2019 May 28. doi: 10.1111/jvh.13146.
    >> Share

  203. NANGIA G, Borges K, Reddy KR
    Use of HCV-infected organs in solid organ transplantation: An ethical challenge but plausible option.
    J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13130.
    >> Share

  204. LAWITZ E, Gane E, Feld JJ, Buti M, et al
    Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.
    J Viral Hepat. 2019 May 20. doi: 10.1111/jvh.13132.
    >> Share

  205. HLAING NKT, Nangia G, Tun KT, Lin S, et al
    High Sustained Virologic Response in Genotypes 3 and 6 with Generic NS5A Inhibitor and Sofosbuvir regimens in chronic HCV in Myanmar.
    J Viral Hepat. 2019 May 18. doi: 10.1111/jvh.13133.
    >> Share

  206. MOORE MS, Greene SK, Bocour A, Brown CM, et al
    Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates.
    J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13124.
    >> Share

  207. MORALES-ARRAEZ D, Alonso-Larruga A, Diaz-Flores F, Garcia Dopico JA, et al
    Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert.
    J Viral Hepat. 2019 May 11. doi: 10.1111/jvh.13122.
    >> Share

  208. GHOSH A, Mondal RK, Romani S, Bagchi S, et al
    Persistent Gamma Delta-T cell Dysfunction in Chronic HCV Infection Despite Direct Acting Antiviral Therapy Induced Cure.
    J Viral Hepat. 2019 May 9. doi: 10.1111/jvh.13121.
    >> Share

  209. LITWIN AH, Drolet M, Nwankwo C, Torrens M, et al
    Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study.
    J Viral Hepat. 2019 May 9. doi: 10.1111/jvh.13119.
    >> Share

    April 2019
  210. BELPERIO PS, Shahoumian TA, Loomis TP, Backus LI, et al
    Real World Effectiveness of Sofosbuvir/velpatasvir/voxilaprevir in 573 Direct-Acting Antiviral Experienced Hepatitis C Patients.
    J Viral Hepat. 2019 Apr 22. doi: 10.1111/jvh.13115.
    >> Share

  211. DVORY-SOBOL H, Han B, Lu J, Yu M, et al
    In Vitro Resistance Profile of Hepatitis C Virus NS5A Inhibitor Velpatasvir in Genotypes 1 to 6.
    J Viral Hepat. 2019 Apr 22. doi: 10.1111/jvh.13116.
    >> Share

  212. BAJIS S, Grebely J, Cooper L, Smith J, et al
    Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112.
    >> Share

  213. INDOLFI G, Bailey H, Serranti D, Giaquinto C, et al
    Treatment and Monitoring of Children with Chronic Hepatitis C in the Pre-DAA Era: a European Survey of 38 Paediatric Specialists.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13111.
    >> Share

  214. KARNSAKUL W, Schwarz KB
    Management of HCV in Children in the Era of DAA's.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13113.
    >> Share

  215. POORDAD F, Sedghi S, Pockros PJ, Ravendhran N, et al
    Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
    J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13109.
    >> Share

  216. BACK D, Belperio P, Bondin M, Negro F, et al
    Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis.
    J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110.
    >> Share

  217. TAMAKI N, Higuchi M, Kurosaki M, Kirino S, et al
    Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct acting antivirals.
    J Viral Hepat. 2019 Apr 11. doi: 10.1111/jvh.13103.
    >> Share

  218. CARABALLO CORTES K, Osuch S, Perlejewski K, Pawelczyk A, et al
    Expression of programmed cell death protein 1 (PD-1) and T cell immunoglobulin and mucin domain-containing molecule-3 (Tim-3) on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus (HCV) infection and in subjec
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13108.
    >> Share

  219. WEN B, Zhang J, Liu W, Tang P, et al
    HBV coinfection with HCV alters circulating Tfh cell distribution and impairs HCV neutralizing antibody responses.
    J Viral Hepat. 2019 Apr 10. doi: 10.1111/jvh.13106.
    >> Share

    March 2019
  220. HAGA H, Saito T, Okumoto K, Tomita K, et al
    Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus are equivalent between genotype B and C in long term.
    J Viral Hepat. 2019 Mar 28. doi: 10.1111/jvh.13099.
    >> Share

  221. SIMMONS R, Ireland G, Ijaz S, Ramsay M, et al
    Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study.
    J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13096.
    >> Share

    February 2019
  222. WILSON EC, Turner C, Lin J, McFarland W, et al
    Hepatitis C seroprevalence and engagement in related care and treatment among transwomen.
    J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13089.
    >> Share

  223. PLATT L, Stengel CM, Nkurunziza M, Muhangi D, et al
    Assessing risk of HIV and hepatitis C among people who inject drugs in East Africa: findings from a rapid assessment.
    J Viral Hepat. 2019 Feb 27. doi: 10.1111/jvh.13088.
    >> Share

  224. TURKOVA A, Volynets GV, Crichton S, Skvortsova TA, et al
    Advanced liver disease in Russian children and adolescents with chronic hepatitis C.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13093.
    >> Share

  225. DORE GJ
    HCV reinfection as a positive indication of high-risk population treatment access.
    J Viral Hepat. 2019 Feb 25. doi: 10.1111/jvh.13092.
    >> Share

  226. LATHAM NH, Pedrana A, Doyle JS, Howell J, et al
    Community-based, point-of-care hepatitis C testing: perspectives and preferences of people who inject drugs.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13087.
    >> Share

  227. VANOPDORP JR, Ferrentino N, Strader DB, Lidofsky SD, et al
    Utility of laboratory monitoring during hepatitis C treatment with ribavirin-free direct acting antiviral regimens.
    J Viral Hepat. 2019 Feb 23. doi: 10.1111/jvh.13083.
    >> Share

  228. IDILMAN R, Demir M, Aladag M, Erol C, et al
    Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
    J Viral Hepat. 2019 Feb 11. doi: 10.1111/jvh.13075.
    >> Share

  229. FERENCI P, Bourgeois S, Buggisch P, Norris S, et al
    Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observation
    J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080.
    >> Share

  230. PALAZZO D, Biliotti E, Esvan R, Volpicelli L, et al
    Vitamin D deficiency and health-related quality of life in chronic hepatitis C.
    J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076.
    >> Share

  231. LAWITZ E, Poordad F, Anderson LJ, Vesay M, et al
    Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection.
    J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079.
    >> Share

    January 2019
  232. BLADOWSKA J, Pawlowski T, Fleischer-Stepniewska K, Knysz B, et al
    Interferon-free Therapy as the Cause of White Matter Tracts and Cerebral Perfusion Recovery in Patients with Chronic Hepatitis C.
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13069.
    >> Share

  233. JACK K, Thomson BJ, Irving WL
    Testing for hepatitis C virus infection in UK Prisons: what actually happens?
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13071.
    >> Share

  234. CHEN WC, Wei CK, Lee JC
    MicroRNA-let-7c suppresses hepatitis C virus replication by targeting Bach1 for induction of heme oxygenase-1 expression.
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13072.
    >> Share

  235. HARRIS RJ, Harris H, Mandal S, Ramsay M, et al
    Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.
    J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13063.
    >> Share

  236. RUANE P, Strasser SI, Gane EJ, Hyland RH, et al
    Sofosbuvir/Velpatasvir/Voxilaprevir for Patients with HCV Who Previously Received a Sofosbuvir/Velpatasvir-Containing Regimen: Results from a Retreatment Study.
    J Viral Hepat. 2019 Jan 21. doi: 10.1111/jvh.13067.
    >> Share

  237. GIROMETTI N, Devitt E, Phillips J, Nelson M, et al
    High rates of unprotected anal sex and use of generic direct-acting antivirals in a cohort of MSM with acute HCV infection.
    J Viral Hepat. 2019 Jan 19. doi: 10.1111/jvh.13066.
    >> Share

  238. XU R, Yu Y, Leitch ECM, Wang M, et al
    HCV genotype 6 prevalence, spontaneous clearance and diversity amongst elderly members of the Li ethnic minority in Baisha County, China.
    J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13062.
    >> Share

  239. KIM HS, Yang JD, El-Serag HB, Kanwal F, et al
    Awareness of Chronic Viral Hepatitis in the United States: An Update from National Health and Nutrition Examination Survey.
    J Viral Hepat. 2019 Jan 10. doi: 10.1111/jvh.13060.
    >> Share

    December 2018
  240. RODRIGO C, Leung P, Lloyd AR, Bull RA, et al
    Genomic variability of within-host hepatitis C variants in acute infection.
    J Viral Hepat. 2018 Dec 22. doi: 10.1111/jvh.13051.
    >> Share

  241. RAMACHANDRAN J, Budd S, Slattery H, Muller K, et al
    Hepatitis C virus infection in Australian psychiatric in-patients: a multicenter study of seroprevalence, risk factors and treatment experience.
    J Viral Hepat. 2018 Dec 21. doi: 10.1111/jvh.13056.
    >> Share

  242. HENGST J, Klein AL, Lunemann S, Deterding K, et al
    Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection.
    J Viral Hepat. 2018 Dec 8. doi: 10.1111/jvh.13050.
    >> Share

  243. POURMARZI D, Hall L, Hepworth J, Smirnov A, et al
    Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of Hepatitis C Virus infection: a mixed method systematic review.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13045.
    >> Share

  244. LEE SS, Kim CY, Kim BR, Cha RR, et al
    Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13047.
    >> Share

  245. RAUWOLF K, Herbruggen H, Zollner S, Thorer H, et al
    Durable control of Hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic hematopoietic stem cell transplantation.
    J Viral Hepat. 2018 Dec 5. doi: 10.1111/jvh.13046.
    >> Share

    November 2018
  246. HOLMES JA, Carlton-Smith C, Kim AY, Dumas EO, et al
    Dynamic Changes in Innate Immune Responses During Direct Acting Antiviral Therapy for HCV Infection.
    J Viral Hepat. 2018 Nov 19. doi: 10.1111/jvh.13041.
    >> Share

  247. KAPILA N, Flocco G, Al Khalloufi K, Zervos XB, et al
    Transplantation of kidneys from HCV viremic donors to HCV viremic recipients followed by early direct acting anti-viral therapy without ribavirin.
    J Viral Hepat. 2018 Nov 18. doi: 10.1111/jvh.13042.
    >> Share

  248. BUTT ZA, Mak S, Gesink D, Gilbert M, et al
    Applying core theory and spatial analysis to identify Hepatitis C Virus infection 'core areas' in British Columbia, Canada.
    J Viral Hepat. 2018 Nov 17. doi: 10.1111/jvh.13043.
    >> Share

  249. SCHULKIND J, Stephens B, Ahmad F, Johnston L, et al
    High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.
    J Viral Hepat. 2018 Nov 13. doi: 10.1111/jvh.13035.
    >> Share

  250. FLAMM S, Mutimer D, Asatryan A, Wang S, et al
    Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis.
    J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038.
    >> Share

  251. SERFATY L, Jacobson I, Rockstroh J, Altice FL, et al
    The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis.
    J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13037.
    >> Share

  252. YOUNG K, Liu B, Bhuket T, Gish RG, et al
    Improved Liver Transplant Waitlist Mortality and Lower Risk of Disease Progression Among Chronic Hepatitis C Patients Awaiting Liver Transplantation After the Introduction of Direct Acting Antiviral Therapies in the United States.
    J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13039.
    >> Share

  253. ORR C, Aartun J, Masur H, Kottilil S, et al
    Characterization of Changes in Intrahepatic Immune Cell Populations During HCV Treatment with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2018 Nov 1. doi: 10.1111/jvh.13034.
    >> Share

  254. YOUNOSSI Z, Papatheodoridis G, Cacoub P, Negro F, et al
    The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.
    J Viral Hepat. 2018;25 Suppl 3:6-14.
    >> Share

    October 2018
  255. WU DB, Jiang W, Wang YH, Chen B, et al
    Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in southwest China: real-world experience of a retrospective study.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13033.
    >> Share

  256. ABDEL GHAFFAR TY, Naghi SE, Gawad MA, Helmy S, et al
    Safety and Efficacy of Combined Sofosbuvir/Daclatasvir Treatment of Children and Adolescents with Chronic Hepatitis C Genotype 4.
    J Viral Hepat. 2018 Oct 31. doi: 10.1111/jvh.13032.
    >> Share

  257. HUANG J, Yin P, Zhang L
    COPII cargo claudin-12 promotes hepatitis C virus entry.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13026.
    >> Share

  258. SARKAR M, Lai JC, Sawinski D, Zeigler TE, et al
    Sex Hormone Levels by Presence and Severity of Cirrhosis in Women With Chronic Hepatitis C Virus (HCV) Infection.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13027.
    >> Share

  259. WANG M, Ping Y, Li Z, Li J, et al
    Polarization of granulocytic myeloid-derived suppressor cells by hepatitis C core protein is mediated via IL-10/STAT3 signaling.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13024.
    >> Share

  260. VAZIRI A, Gimson A, Agarwal K, Aldersley M, et al
    Liver transplant listing for hepatitis C associated cirrhosis and hepatocellular carcinoma has fallen in the United Kingdom since the introduction of direct acting antiviral therapy.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13022.
    >> Share

  261. GIRARDIN F, Hearmon N, Negro F, Eddowes L, et al
    Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing: a Cost-Effectiveness Analysis.
    J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13023.
    >> Share

  262. KNOP V, Hofmann WP, Buggisch P, Klinker H, et al
    Estimation of liver fibrosis by non-commercial serum markers in comparison to transient elastography in patients with chronic hepatitis C virus infection receiving direct acting antiviral treatment.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13021.
    >> Share

  263. MOREY S, Hamoodi A, Jones D, Young T, et al
    Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017.
    >> Share

  264. GOUTZAMANIS S, Doyle J, Higgs P, Hellard M, et al
    Improving hepatitis C direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived-experience.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13020.
    >> Share

  265. MCLEOD A, Weir A, Hutchinson SJ, Goldberg DJ, et al
    Hepatitis C test uptake among historic blood transfusion recipients following media coverage of the Penrose Inquiry and an awareness-raising campaign.
    J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13016.
    >> Share

    September 2018
  266. KWON JA, Dore GJ, Grebely J, Hajarizadeh B, et al
    Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modeling study.
    J Viral Hepat. 2018 Sep 29. doi: 10.1111/jvh.13013.
    >> Share

  267. HERNANDEZ-CONDE M, Fernandez I, Perello C, Gallego A, et al
    Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: results from the Spanish HEPA-C real-world cohort.
    J Viral Hepat. 2018 Sep 28. doi: 10.1111/jvh.13008.
    >> Share

  268. MALAGUTI A, Sani F, Stephens BP, Ahmad F, et al
    Change in injecting behaviour among people treated for hepatitis C virus: the role of intimate partnerships.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13009.
    >> Share

  269. XIA Y, Pan W, Ke X, Skibbe K, et al
    Differential escape of HCV from CD8(+) T cell selection pressure between China and Germany depends on the presenting HLA class I molecule.
    J Viral Hepat. 2018 Sep 27. doi: 10.1111/jvh.13011.
    >> Share

  270. LIU Z, Chen X, Zhang T
    Reply to "The epidemiology of hepatitis B virus infection in China".
    J Viral Hepat. 2018 Sep 21. doi: 10.1111/jvh.13007.
    >> Share

  271. MACIAS J, Tellez F, Rivero-Juarez A, Palacios R, et al
    Early emergence of opportunistic infections after starting direct acting antiviral drugs in HIV/HCV coinfected patients.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13003.
    >> Share

  272. IWAMOTO M, Calzia A, Dublineau A, Rouet F, et al
    Field evaluation of GeneXpert((R)) (Cepheid) HCV performance for RNA quantification in a Genotype 1 and 6 predominant patient population in Cambodia.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13002.
    >> Share

  273. ZHAO H
    The epidemiology of hepatitis B virus infection in China.
    J Viral Hepat. 2018 Sep 10. doi: 10.1111/jvh.13004.
    >> Share

  274. RODGERS MA, Holzmayer V, Vallari A, Olivo A, et al
    Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12996.
    >> Share

  275. DUONG MC, McLaws ML
    Screening hemodialysis patients for hepatitis C in Vietnam: the inconsistency between common hepatitis C virus serological and virological tests.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12994.
    >> Share

  276. VROLING H, Oordt-Speets AM, Madeddu G, Babudieri S, et al
    A systematic review on models of care effectiveness and barriers to Hepatitis C treatment in prison settings in the EU/EEA.
    J Viral Hepat. 2018 Sep 5. doi: 10.1111/jvh.12998.
    >> Share

    August 2018
  277. LAFFERTY L, Rance J, Grebely J, Lloyd AR, et al
    Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12987.
    >> Share

  278. PERPINAN E, Caro-Perez N, Garcia-Gonzalez N, Gregori J, et al
    Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12986.
    >> Share

  279. SAEED S, Moodie EE, Strumpf E, Gill J, et al
    Real-World Impact of Direct Acting Antiviral Therapy on Health-Related Quality of Life in HIV/Hepatitis C Co-Infected Individuals.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12985.
    >> Share

  280. JONES H, Patel P, Sears D
    Electronic Reminders Increase Hepatitis C Screening, referral, treatment and cure.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12988.
    >> Share

  281. MACIAS J, Granados R, Tellez F, Merino D, et al
    Similar recovery of liver function after response to all oral HCV therapy in patients with cirrhosis with and without HIV coinfection.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12990.
    >> Share

  282. LIM SG, Phyo WW, Shah SR, Win KM, et al
    Findings from a large asian chronic hepatitis c real life study.
    J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12989.
    >> Share

  283. DIRKS M, Haag K, Pflugrad H, Tryc AB, et al
    Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
    J Viral Hepat. 2018 Aug 18. doi: 10.1111/jvh.12979.
    >> Share

  284. SINGH A, Kumari S, Kumar P, De A, et al
    Sofosbuvir with NS5A Inhibitors in Hepatitis C Virus (HCV) Infection with Severe Renal Insufficiency.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12983.
    >> Share

  285. MASETTI C, Lionetti R, Lupo M, Siciliano M, et al
    Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis.
    J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12982.
    >> Share

    July 2018
  286. SCOTT N, Sacks-Davis R, Pedrana A, Doyle J, et al
    Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975.
    >> Share

  287. DARVISHIAN M, Janjua NZ, Chong M, Cook D, et al
    Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12977.
    >> Share

  288. PINTILIE H, Brook G
    Commentary: A review of risk of hepatitis B and C transmission through biting or spitting.
    J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12976.
    >> Share

  289. SUGIURA A, Joshita S, Umemura T, Yamazaki T, et al
    Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals.
    J Viral Hepat. 2018 Jul 25. doi: 10.1111/jvh.12973.
    >> Share

  290. KABERG M, Naver G, Hammarberg A, Weiland O, et al
    Incidence and spontaneous clearance of hepatitis C (HCV) in PWID at the Stockholm Needle Exchange - importance for HCV elimination.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12969.
    >> Share

  291. HAYASHI K, Ishigami M, Ishizu Y, Kuzuya T, et al
    Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
    J Viral Hepat. 2018 Jul 11. doi: 10.1111/jvh.12967.
    >> Share

  292. YOUNOSSI ZM, Stepanova M, Henry L, Han KH, et al
    Sofosbuvir and Ledipasvir is Associated with High Sustained Virologic Response and Improvement of Health-Related Quality of Life in East Asian Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jul 4. doi: 10.1111/jvh.12965.
    >> Share

  293. MOHAMED Z, Rwegasha J, Kim JU, Shimakawa Y, et al
    The hepatitis C cascade of care in people who inject drugs in Dar es Salaam, Tanzania.
    J Viral Hepat. 2018 Jul 3. doi: 10.1111/jvh.12966.
    >> Share

    June 2018
  294. HSIEH YH, Patel AV, Loevinsohn GS, Thomas DL, et al
    Emergency Departments at the Crossroads of Intersecting Epidemics (HIV, HCV, Injection Drug Use, and Opioid Overdose) - Estimating HCV Incidence in an Urban Emergency Department Population.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12948.
    >> Share

  295. HARIDY J, Wigg A, Muller K, Ramachandran J, et al
    Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience.
    J Viral Hepat. 2018 Jun 11. doi: 10.1111/jvh.12943.
    >> Share

  296. DINESHA TR, Boobalan J, Sivamalar S, Subashini D, et al
    Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV.
    J Viral Hepat. 2018;25:718-723.
    >> Share

    May 2018
  297. LIU Z, Yang Q, Shi O, Ye W, et al
    The epidemiology of hepatitis B and hepatitis C infections in China from 2004 to 2014: an observational population based study.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12938.
    >> Share

  298. KRAMER JR, Puenpatom A, Erickson K, Cao Y, et al
    Real-World Effectiveness of Elbasvir/Grazoprevir in HCV-Infected Patients in the US Veterans Affairs Healthcare System.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12937.
    >> Share

  299. AISYAH DN, Shallcross L, Hayward A, Aldridge RW, et al
    Hepatitis C among Vulnerable Populations: A Seroprevalence Study of Homeless, People Who Inject Drugs and Prisoners in London.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12936.
    >> Share

  300. MARCO A, Roget M, Cervantes M, Forne M, et al
    Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and non-inmates.
    J Viral Hepat. 2018 May 31. doi: 10.1111/jvh.12940.
    >> Share

  301. JEONG Y, Jin B, Lee HW, Park HJ, et al
    Evolution and Persistence of the Resistance-Associated Substitutions of Hepatitis C Virus after Direct-Acting Antiviral Treatment Failures.
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12932.
    >> Share

  302. CARDOSO AC, Perez RM, de Figueiredo-Mendes C, Carvalho Leite N, et al
    Prevalence and predictive factors of moderate/severe liver steatosis in chronic hepatitis C (CHC) infected patients evaluated with Controlled Attenuation Parameter (CAP).
    J Viral Hepat. 2018 May 16. doi: 10.1111/jvh.12930.
    >> Share

  303. DEMING R, Ford MM, Moore MS, Lim S, et al
    Evaluation of a hepatitis C clinical care coordination program's effect on treatment initiation and cure: A surveillance-based propensity score matching approach.
    J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929.
    >> Share

    April 2018
  304. MARTINELLO M, Bhagani S, Gane E, Orkin C, et al
    Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917.
    >> Share

  305. WADE AJ, McCormack A, Roder C, McDonald K, et al
    Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910.
    >> Share

  306. COUSIEN A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, et al
    Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919.
    >> Share

  307. ANGELIDAKIS G, Hwang JP, Dandachi D, Economides MP, et al
    Universal screening for hepatitis C: a needed approach in patients with hematologic malignancies.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12913.
    >> Share

  308. YOO SH, Kwon JH, Nam SW, Kim HY, et al
    Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients.
    J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12918.
    >> Share

  309. WISLOFF T, White R, Dalgard O, Amundsen EJ, et al
    Feasibility of reaching world health organization targets for hepatitis C and the cost-effectiveness of alternative strategies.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12904.
    >> Share

  310. SCHNELL G, Tripathi R, Beyer J, Reisch T, et al
    Characterization of Demographics and NS5A Genetic Diversity for HCV Genotype 4-Infected Patients with or without Cirrhosis Treated with Ombitasvir/Paritaprevir/Ritonavir.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12906.
    >> Share

  311. MOORE MS, Bocour A, Winters A
    Dialysis Facility Screening and Testing Practices in the Era of Improved Hepatitis C Treatment.
    J Viral Hepat. 2018 Apr 6. doi: 10.1111/jvh.12907.
    >> Share

    March 2018
  312. HOSHINO K, Sugiyama M, Date T, Maruwaka S, et al
    Phylogenetic and phylodynamic analysis of hepatitis C virus subtype 1a in Okinawa, Japan.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12898.
    >> Share

  313. WANG H, Swann R, Thomas E, Innes HA, et al
    Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population-level analysis.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12897.
    >> Share

  314. BOYD SD, Harrington P, Komatsu TE, Naeger LK, et al
    HCV Genotype 4, 5, and 6: Distribution of Viral Subtypes and Sustained Virologic Response Rates in Clinical Trials of Approved Direct-acting Antiviral Regimens.
    J Viral Hepat. 2018 Mar 25. doi: 10.1111/jvh.12896.
    >> Share

  315. NJOUOM R, Siffert I, Texier G, Lachenal G, et al
    The burden of Hepatitis C virus in Cameroon: Spatial epidemiology and historical perspective.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12894.
    >> Share

  316. GOOSSENS N, de Vito C, Mangia A, Clement S, et al
    Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12891.
    >> Share

  317. FEDELI U
    Increasing mortality associated with the more recent epidemic wave of Hepatitis C virus infection in Northern Italy.
    J Viral Hepat. 2018 Mar 13. doi: 10.1111/jvh.12893.
    >> Share

  318. PAPATHEODORIDIS GV, Hatzakis A, Cholongitas E, Baptista-Leite R, et al
    Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    J Viral Hepat. 2018;25 Suppl 1:6-17.
    >> Share

    February 2018
  319. MACLEAN CD, Berger C, Cangiano ML, Ziegelman D, et al
    Impact of Electronic Reminder Systems on Hepatitis C Screening in Primary Care.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12885.
    >> Share

  320. CHEN JY, Ren Y, Yan P, Belina ME, et al
    Tricyclic Antidepressant Use and the Risk of Fibrosis Progression in Hepatitis C-Infected Persons: Results from ERCHIVES.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12884.
    >> Share

  321. LI J, Zhang T, Gordon SC, Rupp LB, et al
    Impact of sustained virological response on risk of type 2 diabetes among hepatitis C patients in the US.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12887.
    >> Share

  322. YOUNOSSI ZM, Tanaka A, Eguchi Y, Henry L, et al
    Treatment of Hepatitis C Virus Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma and Decompensated Cirrhosis in Japan.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12886.
    >> Share

  323. DUARTE G, Williams CJ, Vasconcelos P, Nogueira P, et al
    Capacity to report on mortality attributable to chronic Hepatitis B and C infections by Member States: an exercise to monitor progress toward viral hepatitis elimination.
    J Viral Hepat. 2018 Feb 25. doi: 10.1111/jvh.12882.
    >> Share

  324. OLVEIRA A, Dominguez L, Troya J, Arias A, et al
    Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12883.
    >> Share

  325. CACOUB P, Buggisch P, Carrion JA, S Cooke G, et al
    Direct Medical Costs Associated with the Extrahepatic Manifestations of Hepatitis C Infection in Europe.
    J Viral Hepat. 2018 Feb 24. doi: 10.1111/jvh.12881.
    >> Share

  326. CORTESI PA, Belli LS, Facchetti R, Mazzarelli C, et al
    The optimal timing of Hepatitis C therapy in liver transplant eligible patients: cost-effectiveness analysis of new opportunities.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12877.
    >> Share

  327. HEDENSTIERNA M, Nangarhari A, El-Sabini A, Weiland O, et al
    Cirrhosis, high age and high body mass index are risk factors for persisting advanced fibrosis after sustained virologic response in chronic hepatitis C.
    J Viral Hepat. 2018 Feb 6. doi: 10.1111/jvh.12879.
    >> Share

  328. PREDA CM, Popescu CP, Baicus C, Constantinescu I, et al
    Risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirrhosis treated with Ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12872.
    >> Share

  329. LUXENBURGER H, Grass F, Baermann J, Boettler T, et al
    Differential virus-specific CD8(+) T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12874.
    >> Share

  330. WALKER AJ, Peacock CJ, Pedergnana V, Irving WL, et al
    Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review.
    J Viral Hepat. 2018 Feb 3. doi: 10.1111/jvh.12871.
    >> Share

    January 2018
  331. ALVAREZ-OSSORIO MJ, Sarmento E Castro R, Granados R, Macias J, et al
    Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12867.
    >> Share

  332. GUPTA S, Rout G, Patel AH, Mahanta M, et al
    Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection.
    J Viral Hepat. 2018 Jan 28. doi: 10.1111/jvh.12870.
    >> Share

  333. HARRIS M, Bonnington O, Harrison G, Hickman M, et al
    Understanding hepatitis C intervention success: Qualitative findings from the HepCATT study.
    J Viral Hepat. 2018 Jan 25. doi: 10.1111/jvh.12869.
    >> Share

  334. AYOUB HH, Al Kanaani Z, Abu-Raddad LJ
    Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12864.
    >> Share

  335. AISYAH DN, Shallcross L, Hully AJ, O'Brien A, et al
    Assessing Hepatitis C Spontaneous Clearance and Understanding Associated Factors: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12866.
    >> Share

  336. COLOMBO M, Boccaccio V
    Hepatitis C eradication with DAA and risk of liver cancer recurrence: the debate unrests.
    J Viral Hepat. 2018 Jan 18. doi: 10.1111/jvh.12862.
    >> Share

  337. FLISIAK R, Zarebska-Michaluk D, Janczewska E, Staniaszek A, et al
    Treatment of HCV infection in Poland at the beginning of the interferon-free era - the EpiTer-2 study.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12861.
    >> Share

  338. YOUNG K, Haq K, MacLean S, Dudani R, et al
    Development of a recombinant murine tumor model using hepatoma cells expressing hepatitis C virus (HCV) non-structural antigens.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12856.
    >> Share

  339. FALADE-NWULIA O, Sulkowski MS, Merkow A, Latkin C, et al
    Understanding and addressing hepatitis C reinfection in the oral direct acting antiviral era.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12859.
    >> Share

  340. LAU KC, Osiowy C, Giles E, Lusina B, et al
    Deep Sequencing Shows Low Level Oncogenic Hepatitis B Virus Variants Persisting Post-Liver Transplant Despite Potent Anti-HBV Prophylaxis.
    J Viral Hepat. 2018 Jan 6. doi: 10.1111/jvh.12860.
    >> Share

  341. SCHUTZ A, Moser S, Schwanke C, Schubert R, et al
    Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk for non-adherence to direct-acting antivirals.
    J Viral Hepat. 2018 Jan 5. doi: 10.1111/jvh.12857.
    >> Share

    December 2017
  342. EL KASSAS M, Funk AL, Salaheldin M, Shimakawa Y, et al
    Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12854.
    >> Share

  343. SULKOWSKI MS, Feld JJ, Lawitz E, Felizarta F, et al
    Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12853.
    >> Share

  344. HAJARIZADEH B, Grebely J, Matthews GV, Martinello M, et al
    Uptake of direct acting antiviral treatment for chronic hepatitis C in Australia.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12852.
    >> Share

  345. KOZUKA R, Hai H, Motoyama H, Hagihara A, et al
    The Presence of Multiple NS5A RASs is Associated with the Outcome of Sofosbuvir and Ledipasvir Therapy in NS5A Inhibitor-Naive Patients with Chronic HCV Genotype 1b Infection in a Real-World Cohort.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12850.
    >> Share

  346. MCNAUGHTON AL, Sreenu VB, Wilkie G, Gunson R, et al
    Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12849.
    >> Share

  347. GUBAY F, Staunton R, Metzig C, Abubakar I, et al
    Assessing uncertainty in the burden of Hepatitis C Virus: comparison of estimated disease burden and treatment costs in the UK.
    J Viral Hepat. 2017 Dec 23. doi: 10.1111/jvh.12847.
    >> Share

  348. SIMMONS R, Ireland G, Irving W, Hickman M, et al
    Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12844.
    >> Share

  349. RODRIGUEZ DE SANTIAGO E, Velazquez Kennedy K, Garcia Gonzalez M, Gea Rodriguez F, et al
    HCV-positive lymphoma after sustained virological response with direct-acting antiviral agents: The game is not over after HCV eradication.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12843.
    >> Share

  350. READ SA, Parnell G, Booth D, Douglas MW, et al
    The Antiviral Role of Zinc and Metallothioneins in Hepatitis C Infection.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12845.
    >> Share

  351. ERMAN A, Sathya A, Nam A, Bielecki JM, et al
    Estimating Chronic Hepatitis C Prognosis Using Transient Elastography-Based Liver Stiffness: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2017 Dec 14. doi: 10.1111/jvh.12846.
    >> Share

    November 2017
  352. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    Trends in hepatocellular carcinoma incidence and survival among people with hepatitis C: an international comparison.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12837.
    >> Share

  353. TAMORI A, Abiru S, Enomoto H, Kioka K, et al
    Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy.
    J Viral Hepat. 2017 Nov 30. doi: 10.1111/jvh.12840.
    >> Share

  354. CARLTON-SMITH C, Holmes JA, Naggie S, Lidofsky A, et al
    IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.
    J Viral Hepat. 2017 Nov 29. doi: 10.1111/jvh.12836.
    >> Share

  355. YOUNOSSI ZM, Stepanova M, Schwarz KB, Wirth S, et al
    Quality of Life in Adolescents with Hepatitis C Treated with Sofosbuvir and Ribavirin.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12830.
    >> Share

  356. TANAKA J, Akita T, Ohisa M, Sakamune K, et al
    Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011.
    J Viral Hepat. 2017 Nov 28. doi: 10.1111/jvh.12828.
    >> Share

  357. KEISER O, Giudici F, Mullhaupt B, Junker C, et al
    Trends in hepatitis C-related mortality in Switzerland.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12803.
    >> Share

  358. BROWN A, Hezode C, Zuckerman E, Foster GR, et al
    Efficacy and safety of 12 weeks of elbasvir +/- grazoprevir +/- ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study.
    J Viral Hepat. 2017 Nov 20. doi: 10.1111/jvh.12801.
    >> Share

  359. DUCHESNE L, Lacombe K
    Innovative technologies for point-of-care testing of viral hepatitis in low-resource and decentralized settings.
    J Viral Hepat. 2017 Nov 13. doi: 10.1111/jvh.12827.
    >> Share

  360. BHARDWAJ N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, et al
    Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12825.
    >> Share

  361. SALMON-CERON D, Mondelli MU, Maticic M, Arends JE, et al
    The success of HCV cure: every rose has its thorn.
    J Viral Hepat. 2017 Nov 7. doi: 10.1111/jvh.12823.
    >> Share

  362. HIKITA H, Sato M, Sato M, Soroida Y, et al
    Disappearance of Perihepatic Lymph Node Enlargement after hepatitis C viral eradication with direct acting antivirals.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12819.
    >> Share

  363. DE ARAUJO NETO JM, Coelho HSM, Chindamo MC, da Motta Rezende GF, et al
    Lower levels of dehydroepiandrosterone sulfate are associated with more advanced liver fibrosis in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12812.
    >> Share

  364. MENDES LC, Ferreira PA, Miotto N, Zanaga L, et al
    Elastogram quality assessment score in Vibration Controlled Transient Elastography: Diagnostic performance compared to digital morphometric analysis of liver biopsy in chronic hepatitis C.
    J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12822.
    >> Share

    October 2017
  365. CAMPANA B, Calabrese D, Matter MS, Terracciano LM, et al
    In vivo analysis at the cellular level reveals similar steatosis induction in both HCV genotype 1 and 3 infections.
    J Viral Hepat. 2017 Oct 31. doi: 10.1111/jvh.12816.
    >> Share

  366. MARCELLIN F, Morlat P, Wittkop L, Salmon-Ceron D, et al
    Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12811.
    >> Share

  367. CHOI HY, Kim Y, Cho H, Kim BH, et al
    Risk of diabetes in viral hepatitis B or C patients compared to that in non-infected individuals in Korea, 2002-2013: A population-based cohort study.
    J Viral Hepat. 2017 Oct 27. doi: 10.1111/jvh.12815.
    >> Share

  368. OW MM, Hegazy D, Warshow UM, Cramp ME, et al
    Enhanced natural killer cell activity is found in exposed uninfected recipients of hepatitis C-contaminated blood.
    J Viral Hepat. 2017 Oct 24. doi: 10.1111/jvh.12810.
    >> Share

  369. SALUDES V, Folch C, Morales-Carmona A, Ferrer L, et al
    Community-based screening of hepatitis C with a one-step RNA detection algorithm from dried-blood spots: analysis of key populations in Barcelona, Spain.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12809.
    >> Share

  370. YOUNOSSI ZM, Chan HLY, Dan YY, Lee MH, et al
    Impact of Ledipasvir/Sofosbuvir on the Work Productivity of Genotype 1 Chronic Hepatitis C Patients in Asia.
    J Viral Hepat. 2017 Oct 20. doi: 10.1111/jvh.12808.
    >> Share

  371. WONG NS, Lee CK, Ng SC, Wong HK, et al
    Prevalence of hepatitis C infection and its associated factors in healthy adults without identifiable route of transmission.
    J Viral Hepat. 2017 Oct 15. doi: 10.1111/jvh.12804.
    >> Share

  372. CAMUS G, Han B, Asselah T, Hsieh D, et al
    Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12795.
    >> Share

  373. TANG L, Parker A, Flores Y, Dellario M, et al
    Treatment of hepatitis C with 8 weeks of ledipasvir/sofosbuvir: highly effective in a predominantly black male patient population.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12796.
    >> Share

  374. NORDMANN S, Vilotitch A, Roux P, Esterle L, et al
    Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus co-infected patients (ANRS CO13-HEPAVIH).
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12797.
    >> Share

  375. WEIL C, Mehta D, Koren G, Pinsky B, et al
    Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
    J Viral Hepat. 2017 Oct 6. doi: 10.1111/jvh.12800.
    >> Share

  376. CHEN DS, Hamoudi W, Mustapha B, Layden J, et al
    Strategies to manage hepatitis C virus infection disease burden-Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:44-63.
    >> Share

  377. MAAROUFI A, Vince A, Himatt SM, Mohamed R, et al
    Historical epidemiology of hepatitis C virus in select countries-volume 4.
    J Viral Hepat. 2017;24 Suppl 2:8-24.
    >> Share

  378. DORE GJ, Hatzakis A, Negro F, Waked I, et al
    Estimating HCV disease burden-volume 4 (editorial).
    J Viral Hepat. 2017;24 Suppl 2:4-7.
    >> Share

  379. CHAN HLY, Chen CJ, Omede O, Al Qamish J, et al
    The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4.
    J Viral Hepat. 2017;24 Suppl 2:25-43.
    >> Share

    August 2017
  380. SERPER M, Forde KA, Kaplan DE
    Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.
    J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784.
    >> Share

  381. SHAFRAN SD, Shaw D, Charafeddine M, Agarwal K, et al
    Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III).
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12782.
    >> Share

  382. KITRINOS KM, Corsa AC, Worth A, Hedskog C, et al
    Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12783.
    >> Share

  383. KRAMER JR, El-Serag HB, Taylor TJ, White DL, et al
    Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
    J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728.
    >> Share

  384. BARONE M, Iannone A, Shahini E, Ippolito AM, et al
    A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study.
    J Viral Hepat. 2017 Aug 8. doi: 10.1111/jvh.12765.
    >> Share

  385. MERCHANTE N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, et al
    Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12769.
    >> Share

  386. VON FELDEN J, Scheurich C, Yamamura J, Brainard DM, et al
    Successful treatment of chronic hepatitis C with ground ledipasvir / sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12768.
    >> Share

  387. FOURNIER C, Hoffmann TW, Morel V, Descamps V, et al
    Claudin-1, miR-122 and Apolipoprotein E transduction improves the permissivity of SNU-182, SNU-398 and SNU-449 Hepatoma cells to Hepatitis C Virus.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12767.
    >> Share

    July 2017
  388. HALLAGER S, Ladelund S, Kjaer MS, Madsen LG, et al
    Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study.
    J Viral Hepat. 2017 Jul 27. doi: 10.1111/jvh.12764.
    >> Share

  389. JACKA B, Bray B, Applegate TL, Marshall BD, et al
    Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
    >> Share

  390. SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
    Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
    >> Share

  391. CALVARUSO V, Ferraro D, Licata A, Bavetta MG, et al
    HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct acting antivirals.
    J Viral Hepat. 2017 Jul 13. doi: 10.1111/jvh.12754.
    >> Share

  392. GARDNER SD, Kim J, Baptiste-Brown S, Lopez V, et al
    GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naive chronic hepatitis C subjects.
    J Viral Hepat. 2017 Jul 10. doi: 10.1111/jvh.12753.
    >> Share

  393. SALAZAR-VIZCAYA L, Kouyos RD, Fehr J, Braun D, et al
    On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12752.
    >> Share

    June 2017
  394. BENOVA L, Awad SF, Abu-Raddad LJ
    Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts.
    J Viral Hepat. 2017 Jun 29. doi: 10.1111/jvh.12748.
    >> Share

  395. LI Y, Li Y, Zhang L, Li W, et al
    Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
    J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742.
    >> Share

  396. TENG W, Hsieh YC, Lui KW, Chen WT, et al
    Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12745.
    >> Share

  397. SCHIAVINATO A, Zanetto A, Pantano G, Tosato F, et al
    Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12746.
    >> Share

  398. DIRKS M, Pflugrad H, Weissenborn K
    Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12740.
    >> Share

  399. DE LA TORRE AN, Castaneda I, Ahmad M, Ekholy N, et al
    Audio Computer Assisted Survey Interview and Patient Navigation to Increase Chronic Viral Hepatitis Diagnosis and Linkage to Care in Urban Health Clinics.
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12744.
    >> Share

  400. GADE A
    Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12743.
    >> Share

  401. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12737.
    >> Share

  402. YANG R, Gui X, Xiong Y, Gao S, et al
    Long-term Follow-up of Patients Triply Infected with HIV and Hepatitis B and C Viruses in a Comprehensive Hospital in Central China.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12739.
    >> Share

  403. JOHNSON K, Green PK, Ioannou GN
    Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12731.
    >> Share

  404. EL SHERIF O, Afhdal N, Curry M
    No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12734.
    >> Share

    May 2017
  405. FITCH DN, Dharod A, Campos CL, Nunez M, et al
    Use of Electronic Health Record Clinical Decision Support Tool for HCV Birth Cohort Screening.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12729.
    >> Share

  406. ROB B, Moreno C, Van Vlierberghe H, Bourgeois S, et al
    The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.
    J Viral Hepat. 2017 May 15. doi: 10.1111/jvh.12726.
    >> Share

  407. OSIBOGUN O, Ogunmoroti O, Michos ED, Spatz ES, et al
    HIV/HCV Co-infection and the risk of Cardiovascular Disease: A Meta-analysis.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12725.
    >> Share

  408. MCLEOD A, Cullen BL, Hutchinson SJ, Roy KM, et al
    Limited Impact of Awareness-Raising Campaigns on Hepatitis C Testing Practices among General Practitioners.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12724.
    >> Share

  409. KIM GA, Han S, Kim HD, An J, et al
    Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.
    J Viral Hepat. 2017 May 12. doi: 10.1111/jvh.12723.
    >> Share

  410. WEDEMEYER H, Craxi A, Zuckerman E, Dieterich D, et al
    Real-World Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Patients with HCV Genotype 1 or 4 Infection: a Meta-Analysis.
    J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722.
    >> Share

  411. SHAWA IT, Felmlee DJ, Hegazy D, Sheridan DA, et al
    Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12720.
    >> Share

  412. HLAING NKT, Mitrani RA, Aung ST, Phyo WW, et al
    Safety and Efficacy of Sofosbuvir-Based DAA Regimens for Hepatitis C Virus Genotypes 1 - 4 and 6 in Myanmar: Real-world experience.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12721.
    >> Share

  413. GANE E, Nahass R, Luketic V, Asante-Appiah E, et al
    Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, non-cirrhotic HCV genotype 3-infected patients.
    J Viral Hepat. 2017 May 4. doi: 10.1111/jvh.12719.
    >> Share

    April 2017
  414. STEININGER K, Boyd A, Dupke S, Krznaric I, et al
    HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    J Viral Hepat. 2017 Apr 25. doi: 10.1111/jvh.12707.
    >> Share

  415. PAPASAVVAS E, Azzoni L, Yin X, Liu Q, et al
    HCV viremia associates with NK cell activation and dysfunction in anti retroviral HIV/HCV co-infected subjects.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12714.
    >> Share

  416. DE GROEN RA, Groothuismink ZMA, van Oord G, Kootstra NA, et al
    NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12716.
    >> Share

    March 2017
  417. VUKOTIC R, Conti F, Fagiuoli S, Morelli MC, et al
    Long-term outcomes of DAAs in post-transplant advanced HCV recurrence and fibrosing cholestatic hepatitis.
    J Viral Hepat. 2017 Mar 28. doi: 10.1111/jvh.12712.
    >> Share

  418. BOGLIONE L, Mornese Pinna S, De Nicolo A, Cusato J, et al
    Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12711.
    >> Share

  419. WELZEL TM, Hinrichsen H, Sarrazin C, Buggisch P, et al
    Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708.
    >> Share

  420. AFDHAL N, Everson GT, Calleja JL, McCaughan GW, et al
    Effect of Viral Suppression on Hepatic Venous Pressure Gradient in Hepatitis C With Cirrhosis and Portal Hypertension.
    J Viral Hepat. 2017 Mar 10. doi: 10.1111/jvh.12706.
    >> Share

  421. BUTI M, Dominguez-Hernandez R, Oyaguez I, Casado MA, et al
    Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12704.
    >> Share

  422. CHEW KW, Bhattacharya D, Horwich TB, Yan P, et al
    Performance of the Pooled Cohort Atherosclerotic Cardiovascular Disease Risk Score in Hepatitis C Virus-infected Persons.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12705.
    >> Share

  423. SHRIVASTAVA S, Wilson E, Poonia B, Tang L, et al
    Augmentation of HCV specific immunity and Sustained virological response (SVR).
    J Viral Hepat. 2017 Mar 7. doi: 10.1111/jvh.12702.
    >> Share

  424. CUNNINGHAM EB, Harjarizadeh B, Bretana NA, Amin J, et al
    Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study.
    J Viral Hepat. 2017 Mar 3. doi: 10.1111/jvh.12701.
    >> Share

  425. SMITH HL, Chung RT, Mantry P, Chapman W, et al
    Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    J Viral Hepat. 2017;24:197-206.
    >> Share

  426. TAIT JM, Wang H, Stephens BP, Miller M, et al
    Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.
    J Viral Hepat. 2017;24:207-215.
    >> Share

  427. AGUILERA A, Navarro D, Rodriguez Frias F, Viciana I, et al
    Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (The GEHEP 005 study).
    J Viral Hepat. 2017 Mar 1. doi: 10.1111/jvh.12700.
    >> Share

    February 2017
  428. SHAKER OG, Senousy MA
    Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12696.
    >> Share

  429. DASHTSEREN B, Bungert A, Bat-Ulzii P, Enkhbat M, et al
    Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey among Mongolian adults.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12697.
    >> Share

  430. GRANNAN S
    Understanding Patient Perceptions and Risk for Hepatitis C Screening.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12692.
    >> Share

  431. INGILIZ P
    Martinello et al.,HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2017 Feb 7. doi: 10.1111/jvh.12686.
    >> Share

  432. EL-AKEL W, El-Sayed MH, El Kassas M, El-Serafy M, et al
    National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.
    J Viral Hepat. 2017 Feb 1. doi: 10.1111/jvh.12668.
    >> Share

    January 2017
  433. JANJUA NZ, Islam N, Wong J, Yoshida EM, et al
    Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12684.
    >> Share

  434. DIRKS M, Pflugrad H, Haag K, Tillmann HL, et al
    Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!
    J Viral Hepat. 2017 Jan 24. doi: 10.1111/jvh.12674.
    >> Share

  435. MENDIZABAL M, Reddy KR
    Chronic Hepatitis C and Chronic Kidney disease: Advances, Limitations and Unchartered Territories.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12681.
    >> Share

  436. FERNANDEZ-PONCE C, Munoz-Miranda JP, Arbulo-Echevarria MM, Litran R, et al
    Immune modulation by the Hepatitis C virus core protein.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12675.
    >> Share

  437. ZHOU S, Cella E, Zhou W, Kong WH, et al
    Population dynamics of HCV subtypes in injecting drug-users on methadone maintenance treatment in China associated with economic and health reform.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12677.
    >> Share

  438. VUKOTIC R, Di Donato R, Conti F, Scuteri A, et al
    Secondary prophylaxis of hepatocellular carcinoma: the comparison of direct-acting antivirals with pegylated interferon and untreated cohort.
    J Viral Hepat. 2017;24:13-16.
    >> Share

    December 2016
  439. GOEL A, Sanchez J, Paulino L, Feuille C, et al
    A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12669.
    >> Share

  440. AYOUB H, Abu-Raddad LJ
    Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12671.
    >> Share

  441. MARTINELLO M, Grebely J, Petoumenos K, Gane E, et al
    HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2016 Dec 27. doi: 10.1111/jvh.12666.
    >> Share

  442. TOYODA H, Tada T, Takaguchi K, Senoh T, et al
    Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepa
    J Viral Hepat. 2016 Dec 16. doi: 10.1111/jvh.12665.
    >> Share

  443. PERELLO C, Carrion JA, Ruiz-Antoran B, Crespo J, et al
    Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12637.
    >> Share

  444. MUNOZ-GOMEZ R, Rincon D, Ahumada A, Hernandez E, et al
    Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12664.
    >> Share

  445. CONTI F, Brillanti S, Buonfiglioli F, Vukotic R, et al
    Safety and efficacy of direct acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12663.
    >> Share

  446. ELBASHA E, Greaves W, Roth D, Nwankwo C, et al
    Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    J Viral Hepat. 2016 Dec 13. doi: 10.1111/jvh.12639.
    >> Share

  447. XIONG H, Rong X, Wang M, Xu R, et al
    HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China.
    J Viral Hepat. 2016 Dec 12. doi: 10.1111/jvh.12644.
    >> Share

  448. ALONSO S, Riveiro-Barciela M, Fernandez I, Rincon D, et al
    Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12648.
    >> Share

  449. ALQAHTANI S, Ozaras R, Isakov V, Wyles D, et al
    Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12641.
    >> Share

  450. SHAH SR, Chowdhury A, Mehta R, Kapoor D, et al
    Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12654.
    >> Share

  451. DING Y, Duan S, Ye R, Yang Y, et al
    More Improvement than Progression of Liver Fibrosis Following Antiretroviral Therapy in A Longitudinal Cohort of HIV-infected Patients With or Without HBV and HCV Co-infections.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12658.
    >> Share

  452. GIMENO-BALLESTER V, Buti M, San Miguel R, Riveiro M, et al
    Interferon-free therapies for Patients with Chronic Hepatitis C Genotype 3 Infection: A Systematic Review.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12660.
    >> Share

  453. GITTO S, Gamal N, Andreone P
    NS5A inhibitors for the treatment of hepatitis C infection.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12657.
    >> Share

  454. WARING JF, Davis JW, Dumas E, Cohen D, et al
    Epigenetic analysis of the IFNlambda3 gene identifies a novel marker for response to therapy in HCV-infected subjects.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12661.
    >> Share

  455. CHANG LY, Li Y, Kaplan DE
    Hepatitis C viremia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B-cells.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12659.
    >> Share

  456. ALAEI A, Alaei K, Waye K, Tracy M, et al
    Hepatitis C Infection and Other Drug Related Harms Among Inpatients Who Injected Drugs in Turkey.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12662.
    >> Share

  457. DURIER N, Yunihastuti E, Ruxrungtham K, Kinh NV, et al
    Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12630.
    >> Share

  458. KANAAN N, Raggi C, Goffin E, De Meyer M, et al
    Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12655.
    >> Share

  459. EMMANUEL B, Shardell MD, Tracy L, Kottilil S, et al
    Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12656.
    >> Share

  460. LLANERAS J, Riveiro-Barciela M, Buti M, Esteban R, et al
    Hepatitis C virus genotype 4: Genotype 1's little brother.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12620.
    >> Share

    November 2016
  461. ISLAM N, Krajden M, Gilbert M, Gustafson P, et al
    Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12650.
    >> Share

  462. MCDONALD SA, Innes HA, Aspinall E, Hayes PC, et al
    Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12646.
    >> Share

  463. BARTLETT SR, Wertheim JO, Bull RA, Matthews GV, et al
    A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.
    J Viral Hepat. 2016 Nov 24. doi: 10.1111/jvh.12652.
    >> Share

  464. LAWITZ E, Poordad F, Gutierrez JA, Kakuda TN, et al
    Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    J Viral Hepat. 2016 Nov 23. doi: 10.1111/jvh.12645.
    >> Share

  465. BRUNO G, Saracino A, Fabrizio C, Scudeller L, et al
    Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A "turning-off" effect of liver inflammation?
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12636.
    >> Share

  466. HEZODE C
    Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    J Viral Hepat. 2016 Nov 9. doi: 10.1111/jvh.12635.
    >> Share

  467. KHARABIAN MASOULEH S, Herzig S, Klose L, Roggenhofer E, et al
    Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study.
    J Viral Hepat. 2016 Nov 4. doi: 10.1111/jvh.12634.
    >> Share

  468. RODRIGO C, Eltahla AA, Bull RA, Luciani F, et al
    Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12616.
    >> Share

  469. THOMPSON AJ, Bowden DS
    Vidal LL, et al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment-naive subjects. JVH, 2016, 23(11): 840-849.
    J Viral Hepat. 2016;23:838-839.
    >> Share

    October 2016
  470. ESMAEILI A, Mirzazadeh A, Carter GM, Esmaeili A, et al
    Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.
    J Viral Hepat. 2016 Oct 28. doi: 10.1111/jvh.12628.
    >> Share

  471. EL RAZIKY M, Gamil M, Ashour MK, Sameea EA, et al
    Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naive and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
    J Viral Hepat. 2016 Oct 27. doi: 10.1111/jvh.12625.
    >> Share

  472. LAFFERTY L, Treloar C, Guthrie J, Chambers GM, et al
    Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
    J Viral Hepat. 2016 Oct 24. doi: 10.1111/jvh.12627.
    >> Share

  473. TAPPER EB, Bacon BR, Curry MP, Dieterich DT, et al
    Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    J Viral Hepat. 2016 Oct 11. doi: 10.1111/jvh.12611.
    >> Share

  474. CRISAN D, Radu C, Suciu A, Leach N, et al
    Hepatitis C in nonobese nondiabetic patients: Insulin resistance and the metabolic syndrome make a difference.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12610.
    >> Share

  475. FEVERY B, Verbinnen T, Peeters M, Janssen K, et al
    Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    J Viral Hepat. 2016 Oct 3. doi: 10.1111/jvh.12614.
    >> Share

    September 2016
  476. WONG RJ, Nguyen MT, Trinh HN, Huynh A, et al
    Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
    J Viral Hepat. 2016 Sep 27. doi: 10.1111/jvh.12609.
    >> Share

  477. EMMANUEL B, Sidique N, Zhang X, Poonia B, et al
    Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12618.
    >> Share

  478. ELTAHLA AA, Rodrigo C, Betz-Stablein B, Grebely J, et al
    Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12615.
    >> Share

    July 2016
  479. NISHIKAWA H, Enomoto H, Iwata Y, Kishino K, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.
    J Viral Hepat. 2016 Jul 31. doi: 10.1111/jvh.12575.
    >> Share

    December 2015
  480. ZHOU X, Xu L, Wang W, Watashi K, et al
    Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.
    J Viral Hepat. 2015 Dec 1. doi: 10.1111/jvh.12491.
    >> Share

    August 2015
  481. YOUNOSSI ZM, Stepanova M, Saab S, Ahmed A, et al
    The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.
    J Viral Hepat. 2015 Aug 20. doi: 10.1111/jvh.12449.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016